SUPPLEMENT

FY2026 — Results booklet (double page)

FY2026PDF · 49 pages4.0 MB
Audited Results
and cash dividend declaration
for the year ended 30 June 2026

-- 1 of 49 --

1 	Commentary
12 Group statement of financial position
13 Group income statement
14 Group statement of other comprehensive income
15 Group statement of cash flows
16 Group statement of changes in equity
A 	Notes to the condensed
consolidated financial statements
19 A.1 Segment information
28 A.2 Normalised profit from operations
28 A.3 Earnings, headline earnings and normalised headline
earnings
30 A.4 Revenue from non-insurance activities
30 A.5 Borrowings at amortised cost
32 A.6 Fair value hierarchy
B 	Other significant items in these
results
36 B.1 	Exchange rates to South African Rand used in
the preparation of these results
36 B.2 	Capital management, financial leverage ratio
and covenants
38 B.3.1 Impact of financial risk variances within the SA Life
and UK Life operating segments
39 B.3.2 Purchase of Discovery's Sandton Head office building,
1 Discovery Place (1DP)
39 B.3.3 Partial disposal of interest in Cambridge Mobile
Telematics Incorporated (CMT)
40 B.4 	Cash and cash equivalents
41 B.5 	Consolidation of Discovery Unit Trusts
41 B.6 	Changes in directorate
42 B.7 	Events after reporting date and dividend declaration
in respect of the year ended 30 June 2026
C 	Insurance and reinsurance
contract related disclosure
45 C.1.1 	Insurance and reinsurance contracts disclosures
and reconciliations
49 C.1.2.1 Summary of insurance contracts issued and
reinsurance contracts held
54 C.1.2.2 Movement in insurance contract balances: GMM
60 C.1.2.3 Movement in insurance contract balances: VFA
62 C.1.2.4 Movement in reinsurance contract balances: GMM
66 C.1.2.5 Insurance revenue
68 C.1.2.6 Net investment result
72 C.1.2.7 Summary effect of initially recognised in the period
D 	Accounting policies
76 	D.1 New Accounting Standards and amendments to
published Accounting Standards not yet effective
77 	D.2 Normalised headline earnings
77 	D.3 Basis of preparation
I
Embedded value statement
79 	Table 1: Group embedded value
80 	Table 2: Value of in-force covered business
81 	Table 3: Group embedded value earnings
81 	Table 4: Components of Group embedded value earnings
82 	Table 5: Experience variances
83 	Table 6: Methodology and assumptions changes
84 	Table 7: Value of new business
86 	Table 8: Embedded value economic assumptions
88 	Table 9: Embedded value sensitivity
88 	Table 10: Value of new business sensitivity
Annexure A
91 	New business annualised premium income
92 	Income from non-insurance business lines
92 	Cash conversion ratio
93 	Administration
Contents
Discovery Limited
Registration number 1999/007789/06
1. Group overview and salient results
Salient group results for the year ended 30 June 2026
The Group delivered a strong performance in an external environment shaped by geopolitical uncertainty and policy shifts.
Global equity, bond and currency markets demonstrated heightened volatility and noticeable shifts, with those in South Africa
(SA) showing strong gains, benefitting from a more supportive backdrop. Broader economic conditions remained somewhat
constrained in many global economies, however the structural trends underpinning Discovery's opportunity set continued to
strengthen. Demographic change, rising chronic disease prevalence, deepening fiscal burdens and increasing healthcare costs,
are creating growing pressure on health and financial systems globally, while advances in behavioural science, data and
artificial intelligence (AI) are fundamentally changing how risk can be understood, managed and influenced. Against this
backdrop, Discovery's Shared-value Insurance (SVI) model continues to differentiate the Group and aligns the interests of
customers, partners and shareholders around better outcomes.
Unit 	June 2026 	June 2025 	Change
Group earnings
Normalised profit from operations 	R million 	17 750 	15 210 	17%
Profit attributable to ordinary shareholders 	R million 	13 132 	9 471 	39%
Normalised headline earnings 	R million 	11 795 	9 781 	21%
Headline earnings 	R million 	12 923 	9 625 	34%
Basic earnings per share 	Cents 	1 936.7 	1 402.2 	38%
Basic headline earnings per share 	Cents 	1 925.6 	1 447.0 	33%
Basic normalised headline earnings per share 	Cents 	1 757.6 	1 470.4 	20%
Returns, cash conversion and dividends
Normalised return on equity 	% 	16.5 	15.4 	1.1pp
Annualised return on opening embedded value (RoEV) 	% 	14.1 	15.7 	(1.6)pp
Dividend per share for the year 	Cents 	384 	288 	33%
Cash conversion1 	% 	85 	80 	5pp
Growth drivers
Income from non-insurance business lines1 	R million 	7 282 	6 643 	10%
New business annualised premium income (API)1 	R million 	28 155 	26 486 	6%
Financial position and embedded value
Net asset value 	R million 	82 661 	65 699 	26%
Embedded value 	R million 	142 924 	126 554 	13%
Basic embedded value per share 	R 	212.49 	189.85 	12%
Financial leverage ratio (FLR) 	% 	15.4 	16.8 	1.4pp
1 Refer to Annexure A.
1
Commentary
Discovery Group delivered another year of strong growth and strategic progress
for the year ended 30 June 2026, evidenced by a 17% growth in normalised
operating profit to R17 750 million and further growth in operational cash
generation, representing 85% of profit. Headline earnings and normalised
headline earnings increased by 34% and 21% respectively, resulting in the
normalised return on equity increasing to 16.5%, from 15.4% in the prior year.
DISCOVERY A U D I T E D A N N U A L F I N A N C I A L R E S U L T S F O R T H E Y E A R E N D E D 3 0 J U N E 2 0 2 6

-- 2 of 49 --

1. Group overview and salient results continued
Strong operational delivery demonstrates the scalability of Discovery’s
two composites
Discovery delivered a strong operational performance for the year ended 30 June 2026, with normalised profit from operations
increasing by 17% to R17.75 billion. The result reflects the increasing scale and maturity of the Group's two composites,
Discovery South Africa and Vitality, and validates the strategic foundations established through disciplined investment in
market-leading platforms, proprietary intellectual property and data-driven capabilities.
Discovery South Africa delivered 16% growth in normalised profit from operations, reflecting strong contributions across all
businesses. Vitality increased normalised profit from operations by 21%, dampened by currency movements, following
exceptional growth in the United Kingdom and continued progress across the international portfolio. The year marked the
successful completion of the restructuring of the global business, which included exiting sub-scale activities and consolidating
its international assets and capabilities into a single focused Vitality composite. This will facilitate sharpening strategic focus
and reallocating capital and management capacity towards larger, more scalable opportunities and AI-enabled growth
initiatives.
Normalised headline earnings increased by 21%, as the finance costs declined in line with the Group’s reduction in financial
leverage, and the normalised return on equity improved to 16.5%, from 15.4% in the prior year. Headline earnings increased by
34%, boosted by the gains realised through the early termination of the long-term lease following the acquisition of 1 Discovery
Place, the Group’s head office. The partial sale of the Group’s stake in Cambridge Mobile Telematics (CMT) resulted in a further
increase in basic earnings, which increased 39%. Total new business API increased 6%, driven by strong growth in Discovery
Health and VitalityLife, partly offset by anticipated lower Ping An Health Insurance (PAHI) new business following distribution
changes.
The Group’s embedded value increased to R143 billion, a 14.1% return on embedded value (RoEV), with strong growth in the
value of new business and in profits from non-covered businesses. Favourable non-economic experience variances increased
to R2.6 billion, with each business delivering a positive contribution, reflecting the positive financial dynamics of the model and
particularly strong underlying claims dynamics of the in-force pool of clients across the businesses. Lower long-term interest
rates in SA resulted in a substantial positive impact of economic basis assumptions, which offset lower translated values of
foreign operations given the stronger rand, with a favourable contribution in aggregate.
On the IFRS17 reported accounts, lower SA long-term interest rates also resulted in a significant value uplift for Discovery Life,
with a R12.3 billion gain recognised through Other Comprehensive Income (OCI), rather than earnings. The corresponding
cashflow impact of lower implied future inflation that is extrapolated from the differential in the prevailing market yield curves
at 30 June 2026, will mechanically reduce the Group's systematic interest accretion through insurance finance income and
expense (IFIE) in FY2027 by circa R650 million, all else being equal.
Commentary continued
2
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
1. Group overview and salient results continued
Platforms positioned for growth as SA evolves into the super bank strategy
and the Vitality Shared-value Insurance model accelerates
Discovery SA is progressing into its next strategic phase, creating an integrated ecosystem through the super bank strategy.
Following its quality scaling, Discovery Bank is evolving beyond a standalone banking proposition to becoming the
orchestrating layer for customers' financial and health lives, providing a seamless interface through which customers can
engage with, and derive value from, the broader Discovery ecosystem. The super bank strategy creates a differentiated
competitive advantage that deepens engagement, strengthens cross-selling and supports growth in each South African
business. As the ecosystem scales, it enhances the quality of customer relationships and reinforces the long-term earnings
growth potential of the SA platform.
Globally, structural shifts in demographic, macroeconomic and technology trends have elevated the need and the opportunity
to materially compress morbidity. The Vitality SVI business model leverages a more precise understanding of pricing and
managing health risks, and hyper-personalised product experiences to encourage healthier behaviour. Powered by unique
data assets, behavioural science capabilities, AI-driven personalisation and global partnerships, Vitality is evolving as a scalable
platform that improves health and financial outcomes, reduces risk and enhances long-term value creation. These outcomes
create benefits for individuals, businesses and societies, through the compression of morbidity, and for shareholders, through
superior margins and returns, with strong actuarial outcomes.
Increased financial flexibility in a complex environment
Capital ratios remained strong across every regulated business and the strong operating cash generation provides the Group
with significant financial flexibility. Notwithstanding the fully debt-funded acquisition of 1 Discovery Place, the Group's head
office, the FLR reduced further to 15.4% (or 12.8%, excluding the transaction). The Group’s cash conversion ratio increased
further to 85% of after-tax normalised operating profit, compared with 80% in the prior year, driven by strong and diversified
in-force generation, solid underwriting experience across the Group and Ping An Health Insurance's (PAHI) increased dividend.
Summary of profit from operations and new business performance by
composite for the current period:
R million
Normalised
profit from
operations
% change
(Current year
vs prior year)
New
business API
% change
(Current year
vs prior year)
Discovery Health 	4 629 	+9% 	10 495 	+10%
Discovery Life 	5 872 	+6% 	3 244 	+1%
Discovery Invest 	2 157 	+9% 	3 865 	+13%
Discovery Insure 	1 013 	+24% 	1 390 	+2%
Discovery Bank 	370 	>600%
Other initiatives and central costs1 	(173) 	-66% 	540 	-1%
Discovery SA 	13 868 	+16% 	19 534 	+8%
VitalityHealth 	1 896 	+60% 	2 871 	+1%
VitalityLife 	782 	+23% 	3 027 	+21%
Vitality Global Markets2 	186 	-29%
Ping An Health Insurance (PAHI) 	1 317 	+9% 	2 723 	-10%
Vitality AI3 	(299) 	>200%
Vitality composite 	3 882 	+21% 	8 621 	+3%
Normalised profit from operations 	17 750 	+17%
New business API3 	28 155 	+6%
1 Includes Discovery Vitality SA.
2 Vitality Global Markets incorporates Vitality Network and Vitality Health International Other.
3 Vitality AI also includes Other Vitality central costs.
Commentary continued
3	2

-- 3 of 49 --

2. Business-specific performance
DISCOVERY SOUTH AFRICA
Discovery SA increased normalised operating profit by 16% to R13 868 million and new business
volumes increased by 8% to R19 534 million. The performance reflects the strength of its category-
leading businesses, which are increasingly being unified through the super bank strategy into a single,
integrated customer ecosystem spanning protection, health, wealth and banking. Increased customer
engagement levels were delivered while reducing central and Vitality programme costs over the year.
DISCOVERY BANK
Unit 	June 2026 	June 2025
%
Change
Net non-interest revenue (NIR) 	R million 	1 815 	1 373 	32%
Net Interest income (NII)1 	R million 	1 314 	1 017 	29%
Revenue 	R million 	3 129 	2 390 	31%
Operating profit before new business acquisition costs 	R million 	865 	368 	135%
Normalised profit/(loss) from operations 	R million 	370 	(68) 	>600%
Retail deposits 	R billion 	27.2 	23.3 	17%
Advances 	R billion 	12.9 	9.2 	40%
Average interest-earning assets (IEA)1 	R billion 	27.3 	24.6 	11%
Credit loss ratio (CLR)2 	% 	2.71 	3.03 	(11%)
Number of accounts 	Million 	3.77 	3.00 	26%
Number of clients 	Million 	1.57 	1.25 	26%
1. NII includes the allocation of interest earned on the bond trading portfolio (recognised as fair value gains in the income statement); Average interest-earning assets
(IEA) = treasury assets + retail banking activities.
2. CLR calculated as the expected credit loss (ECL) charge across all products, including overlays and IFRS adjustments, on the period-end advances balance across
the products.
Discovery Bank delivered a profit of R370 million in FY26, compared with a loss of R68 million in FY25. The result reflects
continued growth in scale, leveraging improving operating efficiency and client experience and engagement, increasingly
through the deployment of AI.
The Bank's client base increased 26% to 1.57 million clients, with total accounts increasing 26% to 3.77 million. The Bank
continued to attract new-to-Discovery clients, with 70% of new business originating from outside the Discovery Group.
Continued growth in client engagement and product utilisation drove a 32% increase in non-interest revenue, supporting
higher fee income per client.
Retail deposits increased 17% to R27.2 billion, while gross retail advances grew 40% to R12.9 billion with maintained credit
prudency, through continued momentum in home loans. This balance sheet growth supported a 29% increase in net
interest income, while the credit loss ratio improved to 2.71%.
Revenue increased 31% to R3.1 billion, while operating expenses continued to benefit from economies of scale as the Bank
grows, driving a significant improvement in profitability and returns, while maintaining disciplined risk outcomes.
Commentary continued
4
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
2. Business-specific performance continued
DISCOVERY HEALTH
Unit 	June 2026 	June 2025
%
Change
Normalised profit from operations 	R million 	4 629 	4 259 	9%
New business API 	R million 	10 495 	9 573 	10%
Revenue 	R million 	12 949 	11 888 	9%
Non-scheme revenue as % of total revenue 	% 	17.9 	15.8 	13%
Lives under administration1 	Million 	3.91 	3.80 	3%
1 Prior period lives restated to exclude HealthyCompany, which is in CEB (Corporate and Employee Benefits, within Discovery Life). The impact on other metrics is not
material.
Discovery Health grew normalised operating profit by 9%, notwithstanding a once-off administration fee concession of
R125 million, following strong revenue growth. New business API increased 10%, driven by membership growth across
Discovery Health Medical Scheme (DHMS), supported further by continued growth in restricted schemes and in non-
scheme products, now contributing 17.9% of total revenue. The business continues to invest in AI to improve operational
efficiency, enhance customer experience and healthcare outcomes, and support future growth.
DHMS grew membership while maintaining a strong financial position, with projected unaudited FY26 solvency of 31.3%,
well above the 25% regulatory requirement.
DISCOVERY LIFE
Unit 	June 2026 	June 2025
%
Change
Normalised profit from operations 	R million 	5 872 	5 525 	6%
New business API 	R million 	3 244 	3 203 	1%
New business APE1 	R million 	803 	735 	9%
Premium income 	R million 	19 905 	19 001 	5%
Insurance revenue (IFRS 17) 	R million 	19 601 	19 149 	2%
Solvency ratio 	% 	174 	192 	(18)pp
RoEV 2 	% 	22.8 	15.7 	7.1pp
VNB margin 	% 	3.8% 	2.1% 	1.7pp
New business net value3 	R million 	1 948 	1 460 	33%
1 New business annual premium equivalent (APE), as defined in the Embedded Value statement.
2 Including Discovery Invest and before dividends.
3 Calculated as: New business contractual service margin (CSM) + risk adjustment (RA) minus onerous new business.
Discovery Life’s (DL) operating profit increased by 6% to R5 872 million with continued favourable claims performance. This offset
the R160 million lower systematic interest accretion through IFIE as well as increased onerousness from policy alterations
experience and changes in estimates. The Umbrella Fund unit reached a significant milestone turning profitable over the period.
The Discovery Life Limited embedded value (including Discovery Invest) delivered an RoEV of 23%, driven by lower interest
rates and strong net positive variances. Claims experience demonstrated the effectiveness of the Shared Value Model. The
action plan to remediate policy alterations experience remains on track.
Discovery Life new business annual premium equivalent (APE), as defined in the Embedded Value statement, increased by
9%. DL new business API, increased by a lower 1%, partly impacted by the effect of lower inflation on automatic contribution
increases. DL prioritised quality of business and maintained its leading position in the affluent retail protection market with a
market share of 27%. Within DL’s 3.8% VNB margin, the Individual Life margin increased to 4.7%, from 3.8% in the prior year.
Discovery Life maintained strong liquidity and solvency positions, with liquidity coverage in excess of 200% and a solvency
coverage ratio of 174%, tempered by lower interest rates as well as reinsurance cost optimisation. DL cash generation
(including Discovery Invest) was exceptionally strong, increasing to R3 888 million (prior year R3 327 million), before a
R1 194 million net repayment of financing arrangements (prior year R1 566 million).
Commentary continued
5	4

-- 4 of 49 --

2. Business-specific performance continued
DISCOVERY INVEST
Unit 	June 2026 	June 2025
%
Change
Normalised profit from operations 	R million 	2 157 	1 987 	9%
Assets under administration 	R billion 	205 	179 	15%
Assets under management 	R billion 	146 	124 	18%
% linked assets in Discovery funds 	% 	81 	80 	1pp
Net client cash flows 	R billion 	6.3 	3.2 	97%
New business API 	R million 	3 865 	3 430 	13%
New business APE1 	R million 	2 901 	2 535 	14%
1 New business annual premium equivalent (APE), as defined in the EV statement.
Discovery Invest increased operating profit by 9% to R2 157 million. Assets under management and assets under administration
increased by 18% and 15%, respectively, driven by strong market performance in the first half of the year and positive net
inflows during the year. Earnings growth was tempered by the prior year's asset-liability matching (ALM) gain of R85 million and
a R129 million release relating to tax recoveries from policyholders that had been accrued over previous years. The ALM loss of
R87 million reported at the half year, resulting from a sharp decline in yields, was fully recovered in the second half through
management actions. Excluding the prior year benefits of ALM gains and the tax recoveries releases, earnings increased by 22%,
broadly in line with the growth in average assets under management.
Net client cash flows increased 97% to R6.3 billion, supported by strong linked-business sales and lower redemptions of
guaranteed products. New business APE, excluding annual contribution increases, grew by 14%, driven by linked-business sales,
while sales of Guaranteed Bonds and Fixed Annuities declined in the lower interest rate environment.
DISCOVERY INSURE
Unit 	June 2026 	June 2025
%
Change
Discovery Insure normalised profit from operations 	R million 	955 	739 	29%
Equity accounted profit/(loss) 	R million 	58 	78 	(26%)
Normalised profit from operations 	R million 	1 013 	817 	24%
Operating margin 	% 	14.8 	11.9 	24%
New business API 	R million 	1 390 	1 361 	2%
Insurance revenue 	R million 	6 448 	6 217 	4%
Discovery Insure delivered a 29% increase in normalised profit from operations, with the inclusion of equity accounted profit
from associates delivering a result above R1 billion for the first time. The operating margin improved significantly from 11.9%
to 14.8%, despite claims of around R145 million during May 2026 following severe weather events in the Western Cape and
Eastern Cape. This highlights the effectiveness of management actions in improving the underlying non-weather claims
experience and reinforcing the resilience of the operating margin.
Insurance revenue increased 4% to R6.45 billion, supported by growth in the in-force book, while new business annual premium
income increased 2% despite increasingly competitive market conditions and a softening pricing cycle. This reflects the business'
continued focus on pricing discipline and growth, supported by investments in digital acquisition channels through Discovery
Bank and targeted marketing initiatives.
Commentary continued
6
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
2. Business-specific performance continued
VITALITY
Vitality’s normalised operating profit of R3 882 million increased by 21%, or 26% adjusting for the
rand strengthening, following strong performances in both Vitality UK and Ping An Health Insurance
(PAHI), while Vitality Global Markets (Vitality Network and Vitality Health International Other) was
impacted by adverse Japanese macroeconomics. New business API increased by 3% to R8 621
million, as VitalityLife continued to deliver strong growth, mitigating the expected reduction from
PAHI. Vitality now covers just under 12 million lives outside China, up 14% over the year, including
more than two million clients in the UK. PAHI lives increased 10%, exceeding 35 million.
In the UK, VitalityHealth benefitted from disciplined pricing and favourable claims experience, while
VitalityLife delivered strong new business growth and value generation, both driven through the
continued execution of the Shared-Value Insurance model. Investment spend in Vitality AI accelerated
over the year, with growing application across customer engagement, healthcare, underwriting and
operational processes, applicable to all markets.
During the year, Vitality completed the transition to a regionalised operating model, with the UK
serving as a centre of excellence and cost structures apportioned across the composite to support
the efficient deployment and scaling of capabilities across markets. Vitality Network (VN) and
Vitality Health International Other (VHI) have been incorporated into a single business unit, Vitality
Global Markets, creating a more focused structure to facilitate expanding and deepening
partnerships and capabilities, strengthening distribution, and supporting long-term sustainable
growth within the Shared-Value strategic framework. PAHI's expanded distribution capability has
opened up opportunities for enhanced product innovation, facilitating greater direct engagement
across Vitality.
VITALITY HEALTH
Unit 	June 2026 	June 2025
%
Change
Normalised profit from operations 	£ million 	83.6 	50.6 	65%
R million 	1 896 	1 188 	60%
Insurance revenue (earned premiums) 	£ million 	909.0 	814.5 	12%
R million 	20 611 	19 124 	8%
Margin 	% 	9.2 	6.2 	3pp
New business API 	£ million 	126.6 	121.4 	4%
R million 	2 871 	2 851 	1%
Lives covered 	Million 	1.08 	1.06 	2%
VitalityHealth’s (VH) operating profit rose by 65% to £83.6 million (60% to R1 896 million). Strong premium growth and
particularly favourable claims experience resulted in a 9.2% operating margin, significantly above the 7.5% margin
objective. VH continued to invest in healthcare risk management, primary care assets, and digital servicing to enhance
efficiency and care outcomes.
Market conditions became more challenging, with financial pressures on businesses and consumers resulting in slower
growth across the UK private medical insurance market, amid intensifying competition. Against this backdrop, VH’s 12%
increase in earned premiums demonstrates its successful execution of maintaining high‑quality business at appropriate
pricing, notwithstanding more moderate growth in new business of 4%, and net lives of 2%.
Commentary continued
7	6

-- 5 of 49 --

2. Business-specific performance continued
VITALITY LIFE
Unit 	June 2026 	June 2025
%
Change
Normalised profit from operations 	£ million 	34.5 	27.1 	27%
R million 	782 	637 	23%
Earned premiums 	£ million 	514 	448 	15%
R million 	11 649 	10 514 	11%
New business API 	£ million 	133.5 	106.4 	25%
R million 	3 027 	2 499 	21%
New business APE1 	£ million 	111.1 	89.2 	25%
R million 	2 519 	2 094 	20%
Insurance revenue 	£ million 	405.0 	342.8 	18%
R million 	9 184 	8 050 	14%
Lives covered 	Million 	1.01 	0.90 	12%
VNB margin 	% 	2.3 	0.2 	2.1pp
New business net value2 	£ million 	78.2 	46.9 	67%
R million 	1 773 	1 101 	61%
1 New business annual premium equivalent (APE), as defined in the EV statement.
2 New business net value (NB CSM + NB RA minus onerous NB) excludes the impact of new reinsurance contracts attaching to the in-force book in the year.
New business net value including all contracts incepted was £62.4 million (i.e., £78.2 million minus £15.8 million for Value-In-Force monetisation).
VitalityLife's (VL) operating profit increased by 27% to £34.5 million (23% to R782 million), benefitting from favourable
claims experience and lower cashflow variances, alongside continued strong underlying business performance.
VL maintained strong sales momentum, with new business increasing by 25% and new business net value by 67%. This
was driven by advanced price optimisation and an expanded distribution footprint in a market that is growing, combined
with disciplined expense management. VL continued to benefit from its differentiated Shared-Value Insurance model,
supporting both growth and member engagement in an increasingly competitive market.
Robust retention coupled with new business growth saw lives covered and earned premiums increase by 11% and 15%,
respectively.
VITALITY GLOBAL MARKETS (VITALITY NETWORK AND VITALITY HEALTH INTERNATIONAL)
Unit 	June 2026 	June 2025
%
Change
Revenue1 	US$ million 	146.3 	163.1 	(10%)
R million 	2 472 	2 962 	(17%)
Normalised profit from operations 	US$ million 	11.0 	14.5 	(24%)
R million 	186 	263 	(29%)
Integrated API by Insurance Partners 	US$ million 	2 153 	1 951 	10%
R million 	34 830 	35 423 	(2%)
Number of lives 	Million 	9.78 	8.40 	16%
1 Refer to Annexure A
Normalised profit from operations for Vitality Global Markets declined 24% to US$11 million (29% to R186 million),
significantly impacted by adverse Japanese macroeconomics. The successful partnership with Sumitomo Life has driven a
large Yen-based contract asset, which is expected to unwind at a high rate, but which gave rise to earnings volatility in the
current period. The combination of a decline in the Japanese Yen and higher Japanese interest rates recorded at the end of
the year resulted in a negative revaluation of US$11.6 million, versus a prior year gain of US$4 million. Excluding the impact
of these economics, profits increased by 115%, reflecting rapid progress for VHI Other, while VN builds for greater longer-
term scale and value.
Commentary continued
8
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
2. Business-specific performance continued
Vitality Network (VN) has continued to actively manage its partnership portfolio, focusing its resources on opportunities with
strong strategic alignment, scale potential, and long-term commitment. The planned exit of certain markets had some revenue
impact, however the impact on profit was largely as a consequence of the adverse Japanese economic effects. Revenues
declined 22% and the operating margin declined to 16%, however excluding these economic effects, the margin improved for
the year. Vitality integrated new business increased 10%, despite a decline in a core South-East Asian market following elevated
prior period sales due to a regulatory change. Vitality is making good progress towards securing new long-term partnerships
across several markets in Europe, while also expanding beyond traditional insurance partnerships into adjacent areas such as
health systems and government-related opportunities.
VitalityHealth USA (“VHUS”) has been building and cautiously acquiring core capabilities and distribution to create a
differentiated integrated health solution to address a large and growing segment within the US healthcare market. The
acquisition of WellSpark in November 2024 has exceeded expectations and contributed meaningfully to improved financial
performance, while the acquisition of Ramp Health in March 2026 expanded the business’ coaching, clinical and workplace
health capabilities. VHUS increased revenues 22%, as it continued to deploy its Vitality AI-enabled engagement solutions and
increased its health plan footprint to 10 health plans in key market segments. Total covered membership increased to
3.6 million at the end of the reporting period. Post the year end, VHUS finalised the acquisition of Icario, which covers 11 million
lives, to accelerate and complement its capability for the large Government-sponsored market. VHUS has also finalised a
partnership with HealthEquity, the largest Health Savings Account custodian in the U.S. market by number of accounts, with
more than 10 million Health Savings Accounts.
Amplify Health (“AH”) continued to deliver award-winning, AI-enabled and data-driven health technology solutions across the
Asia-Pacific region, including integrated product offerings with multi-year value-share economics in four key markets. AH
expanded its regional footprint through a three-year partnership with Star Health, India’s largest standalone health insurer,
to deploy AI-led claims intelligence and healthcare analytics solutions.
Commentary continued
9	8

-- 6 of 49 --

2. Business-specific performance continued
PING AN HEALTH INSURANCE (PAHI)
Annual results DSY
PAHI half-year
(6-month) period1
Unit
June
2026
June
2025
%
Change
June
2026
June
2025
%
Change
PAHI after-tax operating profit
(24.99%), after Discovery’s costs2 	R million 	1 317 	1 206 	9% 	744 	782 	(5%)
PAHI pre-tax profit (100%) 	RMB million 	3 326 	2 544 	31% 	1 882 	1 638 	15%
Profit before investment income and
gains (100%) 	RMB million 	1 695 	1 398 	21% 	1 013 	1 092 	(7%)
Investment income and gains (100%) 	RMB million 	1 631 	1 146 	42% 	869 	547 	59%
New business (100%)3 	RMB million 	4 510 	4 807 	(6%) 	2 626 	3 064 	(14%)
New business (25%)3 	R million 	2 723 	3 023 	(10%) 	1 574 	1 935 	(19%)
Earned premium (100%)3 	RMB million 	19 323 	17 807 	9% 	9 823 	9 521 	3%
Written premium (100%)3 	RMB million 	20 719 	18 824 	10% 	12 448 	11 372 	9%
Lives3 	Million 	35.4 	32.1 	10% 	35.4 	32.1 	10%
Investable assets 	RMB billion 	29.5 	26.4 	12% 	29.5 	26.4 	12%
1 PAHI half-year calendar performance has been included to align with the Chinese industry comparable reporting.
2 Costs include Vitality apportioned costs, which increased $10.8 million.
3 PAHI own licence business.
The Group’s share of PAHI’s after-tax operating profit increased by 9% to R1 317 million, building on a strong prior-year
result. PAHI’s profit before investment income and gains grew by 21% RMB1.7 billion for the year, reflecting improved
underlying business performance driven by innovative offerings, stronger customer retention, and continued cost
discipline. PAHI’s profit before tax increased 31%, benefitting from exceptional investment gains, amid a strong equity
market environment, with PAHI’s technology-focused investment portfolio significantly outperforming the broader market.
The net margin improved to 13% for the year, despite absorbing approximately RMB100 million of additional tax following
the removal of tax-exempt treatment on dividends from certain investment vehicles from January 2026.
The anticipated decline in new business, down 6% to RMB4.5 billion, followed discontinuation of distribution of the core
eShengBao product range through the Ping An Life (PAL) channel. However, strong growth from the other channels
mitigated the decline. In addition, strong retention rates drove improved growth in renewal premiums from both the PAL
channel back book and alternative distribution channels. As a result, earned premiums increased by 9% to RMB19.3 billion,
6% ahead of the industry. The number of insured lives increased by 10% to 35.4 million, reflecting strong customer
acquisition enabled by enhanced recognition of product innovation and deeper integration of health and wellness
services.
PAHI’s comprehensive solvency ratio (unaudited) remained strong at 289% as at Q2 CY26, compared with 312% at Q4
CY25, demonstrating continued capital strength and prudent capital management. The Group received a cash dividend
of RMB 207 million in June 2026, compared with RMB 166 million in the prior year. This represented the Group’s share of
a 35% dividend payout ratio.
Commentary continued
10
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Prospects and dividend
Discovery’s growth strategy is based on the efficacy, repeatability, and scalability of its model through organic growth and
global partnerships. The acceleration of technological and demographic trends reinforces the relevance of the model and
Discovery’s unique data. The Group is well positioned for sustained growth through focused composites; Discovery South
Africa and Vitality, with strong platforms in each, resulting in growth in earnings, cash generation, and return on equity, as well
as lower leverage. The Group established a five-year ambition for normalised profit from operations to grow between 15% to
20% on a compound basis from the end of 2024 to 2029. After the strong performance in the first two years of this period, the
Group now expects to achieve compound growth in the middle to upper end of this ambition over the five-year period.
Given the continued improvement in financial flexibility, the Group has declared its final ordinary dividend for the period at
273 cents per share, up 36% on the prior period, representing an annual cover ratio of 4.5 times on normalised headline
earnings, an improvement from 5 times cover in the prior year.
Notes to analysts
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company's
external auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/investor-relations and go to Financial and annual reports.
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Group Chief Executive
Sandton
2 September 2026
Commentary continued
11	10

-- 7 of 49 --

R million
Group
2026
Group
2025
Assets
Goodwill 	5 105 	5 429
Intangible assets 	7 276 	7 542
Property and equipment 	5 938 	3 266
Assets arising from insurance contracts issued 	63 681 	48 047
Assets arising from reinsurance contracts held 	1 049 	962
Deferred tax asset 	3 771 	4 886
Assets arising from contracts with customers 	3 674 	3 722
Investment in equity-accounted investees 	9 190 	8 989
Financial assets
– Loans and advances to customers at amortised cost 	12 999 	8 513
– Investments at amortised cost 	15 077 	12 812
– Investments at fair value through other comprehensive income 	– 	14
– Investments at fair value through profit or loss 	222 884 	193 776
– Derivative financial instruments at fair value through profit or loss 	147 	63
Contract receivables and other receivables 	7 943 	7 368
Non-current assets held for sale 	– 	62
Current tax asset 	35 	31
Cash and cash equivalents 	22 904 	21 968
TOTAL ASSETS 	381 673 	327 450
Equity
Capital and reserves
Ordinary share capital and share premium 	12 205 	11 358
Perpetual preference share capital 	779 	779
Other reserves 	10 115 	4 921
Retained earnings 	59 569 	48 646
Equity attributable to equity holders of the Company 	82 668 	65 704
Non-controlling interest 	(7) 	(5)
TOTAL EQUITY 	82 661 	65 699
Liabilities
Liabilities arising from insurance contracts issued 	136 139 	118 878
Liabilities arising from reinsurance contracts held 	10 686 	9 121
Deferred tax liability 	12 907 	8 755
Contract liabilities to customers 	1 842 	1 516
Third-party interest in consolidated funds 	40 901 	35 932
Financial liabilities
– Borrowings at amortised cost 	18 692 	20 046
– Other financial payables at amortised cost 	8 898 	9 148
– Deposits from customers 	27 202 	23 326
– Investment contracts at fair value through profit or loss 	38 614 	32 188
– Derivative financial instruments at fair value through profit or loss 	117 	135
Other payables 	2 458 	2 333
Current tax liability 	556 	373
TOTAL LIABILITIES 	299 012 	261 751
TOTAL EQUITY AND LIABILITIES 	381 673 	327 450
Group statement of financial position
as at 30 June 2026
12
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
R million
Group
2026
Group
2025
Insurance revenue 	61 442 	57 713
Insurance service expenses 	(51 577) 	(49 028)
Net expenses from reinsurance contracts 	(1 124) 	(1 306)
Insurance service result 	8 741 	7 379
Net financial result from insurance finance income and expense 	(13 295) 	(13 088)
– Net finance expense from insurance contracts 	(12 831) 	(12 665)
– Net finance expense from reinsurance contracts 	(464) 	(423)
Investment income using the effective interest rate method 	1 117 	998
Net fair value gains on financial assets at fair value through profit or loss 	26 139 	25 818
Fair value adjustment to liabilities under investment contracts 	(3 894) 	(3 810)
Third party interest: fair value adjustment to liabilities under investment contracts 	(4 317) 	(4 394)
Other gains on financial instruments 	– 	(9)
Net insurance and investment results 	14 491 	12 894
Fee income from administration businesses 	14 599 	14 326
Vitality income 	5 619 	5 322
Net banking fee and commission income 	2 099 	1 695
– Banking fee and commission income 	2 749 	2 238
– Banking fee and commission expense 	(650) 	(543)
Net bank interest and similar income 	1 256 	966
– Bank interest and similar income using the effective interest rate 	2 570 	2 203
– Bank interest and similar expense using the effective interest rate 	(1 314) 	(1 237)
Other income 	3 810 	1 832
Non-insurance revenue and income 	27 383 	24 141
Net income 	41 874 	37 035
Non-insurance acquisition costs 	(336) 	(384)
Expected credit losses 	(350) 	(279)
Marketing and administration expenses 	(22 575) 	(21 765)
Impairment of goodwill 	– 	(20)
Operating profit 	18 613 	14 587
Gain/(loss) on dilution and disposal of equity-accounted investments 	261 	(32)
Share of net profits from equity-accounted investments 	1 523 	1 215
Profit before financing and income tax 	20 397 	15 770
Interest expense on borrowings and lease liabilities 	(1 817) 	(2 087)
Foreign exchange losses 	(123) 	(36)
Profit before income tax 	18 457 	13 647
Income tax expense 	(5 239) 	(4 089)
Profit for the year 	13 218 	9 558
Profit attributable to:
– Ordinary shareholders 	13 132 	9 471
– Preference shareholders 	86 	93
– Non-controlling interest 	– 	(6)
13 218 	9 558
Earnings per share for profit attributable to ordinary shareholders of the company
during the year (cents):
– Basic 	1 936.7 	1 402.2
– Diluted 	1 925.5 	1 394.9
Group income statement
for the year ended 30 June 2026
13
Results
	commentary
Group statement of
	financial position
Group income
	statement
Group statement
	of other
	comprehensive
	income
Group statement
	of cash flows
Group
	statement of
	changes in equity
Notes to the condensed
	consolidated financial
	statements
Other
	significant items
	in these results
Insurance and
	reinsurance
	contract related
	disclosures
Restatements
 
Accounting
	policies
Embedded value
	statement
 
Annexure A
 
Administration
12

-- 8 of 49 --

R million
Group
2026
Group
2025
Profit for the year 	13 218 	9 558
Income and expenses that will be reclassified to profit or loss when specific
conditions are met:
Currency translation differences 	(2 766) 	998
Unrealised (losses)/gains 	(2 848) 	1 032
Tax on unrealised losses/(gains) 	82 	(34)
Cash flow hedges 	52 	(104)
– Unrealised losses 	(10) 	(106)
– Tax on unrealised losses 	2 	–
– Losses reclassified to profit or loss 	60 	2
Net finance income/ (expenses) from insurance contracts held 	8 888 	2 186
– Unrealised income/(expense) 	12 154 	2 961
– Tax on unrealised (income)/expense 	(3 266) 	(775)
Net finance (expense)/income from reinsurance contracts held 	(471) 	(282)
– Unrealised (expense)/income 	(645) 	(382)
– Tax on unrealised expense/(income) 	174 	100
Share of other comprehensive income from equity-accounted investments 	(433) 	(120)
– Change in fair value of equity instruments at fair value through other comprehensive income 	(45) 	16
– Currency translation differences 	(388) 	(136)
Total income and expenses that will be reclassified to profit or loss when specific
conditions are met 	5 270 	2 678
Income and expenses that will not be reclassified to profit or loss:
Equity instruments held at fair value through other comprehensive income 	– 	(2)
– Change in fair value of equity instruments at fair value through other comprehensive income 	– 	(2)
– Tax on change in fair value of equity instruments at fair value through other
comprehensive income 	– 	*
Share of other comprehensive (loss)/income from equity-accounted investments 	* 	23
– Change in fair value of equity instruments at fair value through other comprehensive income 	* 	23
Total income and expenses that will not be reclassified to profit or loss 	– 	21
Other comprehensive income for the year, net of tax 	5 270 	2 699
Total comprehensive income for the year 	18 488 	12 257
Attributable to:
– Ordinary shareholders 	18 403 	12 169
– Preference shareholders 	86 	93
– Non-controlling interest 	(1) 	(5)
Total comprehensive income for the year 	18 488 	12 257
* Amount is less than R500 000.
Group statement of other comprehensive income
for the year ended 30 June 2026
14
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
R million
Group
2026
Group
2025
Cash flows from operating activities 	7 036 	8 667
Cash generated from operations 	2 867 	1 289
Interest received 	3 309 	2 955
Interest paid 	(3 105) 	(2 877)
Taxation paid 	(2 825) 	(1 867)
Net movement in operating assets and liabilities 	6 790 	9 167
– Increase in operating assets 	(13 346) 	(11 060)
– Increase in operating liabilities 	20 136 	20 227
Cash flows from investing activities 	(4 798) 	(1 823)
Purchase of property and equipment 	(4 533) 	(294)
Proceeds from disposal of property and equipment 	2 	3
Purchase of intangible assets 	(1 510) 	(1 682)
Proceeds from disposal of intangible assets 	2 	–
Acquisition of business net of cash 	(167) 	(316)
Additional investment in equity-accounted investments 	(17) 	(24)
Proceeds from disposal of associates and joint ventures 	801 	–
Proceeds from disposal of sale of non-current asset held for sale 	58 	–
Dividends from equity-accounted investments 	566 	490
Cash flows from financing activities 	(538) 	(4 016)
Dividends paid to ordinary shareholders 	(2 119) 	(1 614)
Dividends paid to preference shareholders 	(86) 	(93)
Proceeds from borrowings 	13 050 	3 264
Repayment of borrowings and lease liabilities1 	(11 383) 	(5 573)
Net increase in cash and cash equivalents 	1 700 	2 828
Cash and cash equivalents at beginning of the year 	21 966 	18 965
Effects of exchange rate changes on cash and cash equivalents 	(762) 	173
Cash and cash equivalents at end of the year 	22 904 	21 966
Reconciliation to statement of financial position
Cash and cash equivalents 	22 904 	21 968
Bank overdraft included in borrowings at amortised cost 	– 	(2)
Cash and cash equivalents at end of the year 	22 904 	21 966
1 The line item “Repayment of borrowings” has been renamed to “Repayment of borrowings and lease liabilities” to improve clarity and better reflect the underlying
transactions included in the balance. This change relates to presentation only.
Group statement of cash flows
for the year ended 30 June 2026
15
Results
	commentary
Group statement of
	financial position
Group income
	statement
Group statement
	of other
	comprehensive
	income
Group statement
	of cash flows
Group
	statement of
	changes in equity
Notes to the condensed
	consolidated financial
	statements
Other
	significant items
	in these results
Insurance and
	reinsurance
	contract related
	disclosures
Restatements
 
Accounting
	policies
Embedded value
	statement
 
Annexure A
 
Administration
14

-- 9 of 49 --

Attributable to equity holders of the Company 	Attributable to equity holders of the Company
R million
Share capital
and share
premium
Perpetual
preference
share capital
Share-based
payment
reserve
Investment
reserve1
Insurance
finance
reserve
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest 	Total Equity
Year ended 30 June 2026
At beginning of the year 	11 358 	779 	1 480 	118 	(2 928) 	6 375 	(124) 	48 646 	65 704 	(5) 	65 699
Total comprehensive income for the year 	– 	86 	– 	(45) 	8 417 	(3 153) 	52 	13 132 	18 489 	(1) 	18 488
Profit for the year 	– 	86 	– 	– 	– 	– 	– 	13 132 	13 218 	– 	13 218
Other comprehensive income 	– 	– 	– 	(45) 	8 417 	(3 153) 	52 	– 	5 271 	(1) 	5 270
Transactions with owners 	847 	(86) 	(54) 	(23) 	– 	– 	– 	(2 209) 	(1 525) 	(1) 	(1 526)
Share issue 	625 	– 	– 	– 	– 	– 	– 	(9) 	616 	– 	616
Increase in treasury shares 	(625) 	– 	– 	– 	– 	– 	– 	– 	(625) 	– 	(625)
Delivery of treasury shares 	847 	– 	(777) 	– 	– 	– 	– 	(70) 	– 	– 	–
Modification of share based payment settlement 	– 	– 	(101) 	– 	– 	– 	– 	(40) 	(141) 	– 	(141)
Changes in ownership interests 	– 	– 	– 	– 	– 	– 	– 	5 	5 	– 	5
Transfer among reserves 	– 	– 	– 	(23) 	– 	– 	– 	24 	1 	(1) 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	824 	– 	– 	– 	– 	– 	824 	– 	824
Dividends paid to preference shareholders 	– 	(86) 	– 	– 	– 	– 	– 	– 	(86) 	– 	(86)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(2 119) 	(2 119) 	– 	(2 119)
At end of the year 	12 205 	779 	1 426 	50 	5 489 	3 222 	(72) 	59 569 	82 668 	(7) 	82 661
Year ended 30 June 2025
At beginning of the year 	10 667 	779 	1 433 	81 	(4 832) 	5 514 	(20) 	40 829 	54 451 	– 	54 451
Total comprehensive income for the year 	– 	93 	– 	37 	1 904 	861 	(104) 	9 471 	12 262 	(5) 	12 257
Profit for the year 	– 	93 	– 	– 	– 	– 	– 	9 471 	9 564 	(6) 	9 558
Other comprehensive income 	– 	– 	– 	37 	1 904 	861 	(104) 	– 	2 698 	1 	2 699
Transactions with owners 	691 	(93) 	47 	– 	– 	– 	– 	(1 654) 	(1 009) 	– 	(1 009)
Share issue 	626 	– 	– 	– 	– 	– 	– 	(23) 	603 	– 	603
Increase in treasury shares 	(626) 	– 	– 	– 	– 	– 	– 	– 	(626) 	– 	(626)
Delivery of treasury shares 	691 	– 	(674) 	– 	– 	– 	– 	(17) 	– 	– 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	721 	– 	– 	– 	– 	– 	721 	– 	721
Dividends paid to preference shareholders 	– 	(93) 	– 	– 	– 	– 	– 	– 	(93) 	– 	(93)
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(1 614) 	(1 614) 	– 	(1 614)
At end of the year 	11 358 	779 	1 480 	118 	(2 928) 	6 375 	(124) 	48 646 	65 704 	(5) 	65 699
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured
at FVOCI, in terms of IFRS 9 Financial Instruments.
Group statement of changes in equity
for the year ended 30 June 2026
16
17
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
16

-- 10 of 49 --

18
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
ANotes to the condensed
consolidated
financial statements
19 A.1 Segment information
28 A.2 Normalised profit from operations
28 A.3 Earnings, headline earnings and
normalised headline earnings
30 A.4 Revenue from non-insurance
activities
30 A.5 Borrowings at amortised cost
32 A.6 Fair value hierarchy
A.1 	Segment information
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief
operating decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes
strategic decisions regarding these businesses.
An operating segment is a component of an entity:
(a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and
expenses relating to transactions with other components of the same entity.
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be
allocated to the segment and assess its performance; and
(c) For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up
operations may be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative
thresholds:
(a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is
10 percent or more of the combined revenue, internal and external, of all operating segments.
(b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount,
of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined
reported loss of all operating segments that reported a loss; and
(c) Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and
separately disclosed, if management believes that information about the segment would be useful to users of the
financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with
information about other operating segments that do not meet the quantitative thresholds to produce a reportable
segment only if the operating segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to
customers and the location of the markets served.
A. 	Notes to the condensed consolidated financial
statements
19	18

-- 11 of 49 --

A.1 	Segment information continued
The following summary describes the operations of each of the Group’s reportable segments:
A. 	Notes to the condensed consolidated financial
statements continued
20
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
3
2
1
SA HEALTH
■ Administers and provides managed care services to medical
schemes in South Africa.
■ Renders administration services to other business segments
within the Group.
■ Together with Medical Services Organisation International
(MSO), a subsidiary company, delivers health insurance,
healthcare risk management and third-party administration
services within rest of Africa markets.
■ Offers non-medical scheme-related products such as Gap
Cover for unexpected medical costs and Flexicare – which
provides quality, affordable access to primary healthcare for
employees unable to access medical scheme benefits.
SA INVEST
Offers, through a range of investment fund choices, including
Discovery managed unit trusts, a comprehensive and flexible range
of investment choices. These products are sold through a number
of investment wrappers, including Discovery Life policies, and are
offered to individuals in South Africa.
SA LIFE
Offers a range of insurance and financial solutions to the
Group’s clients against the financial impact of lifestyle-
changing events in South Africa. This segment also includes
Corporate and Employee Benefits (CEB), which comprises
the Group Risk, Umbrella and HealthyCompany offerings.
SA INSURE
Offers a range of personal line insurance (motor, building,
household content and portable possessions) to the
Group’s SA clients against the financial impact of loss or
damage. The segment also includes SA Insure’s equity-
accounted interests including Cambridge Mobile Telematics
(CMT).
SA BANK
Offers retail banking solutions, including deposits and loans
and advances, to clients in the South African market. The
Bank is still in a start-up phase.
UK HEALTH
Offers consumer-engaged private medical insurance products
to employer groups and individuals in the UK. All contracts in
this segment are short-term insurance contracts.
UK LIFE
Offers a risk-only life assurance product. All contracts in
this segment are long-term assurance contracts offered
to both employer groups and individuals in the UK.
All other segments
Includes those businesses that are not operating segments, as well as those operating segments that
do not meet the quantitative thresholds for separate reporting. It includes:
Discovery SA
■ SA Vitality: which offers health and lifestyle benefits with
selected partners to the Group’s SA clients.
■ SA Insure commercial: provides commercial short-term risk
insurance products to the South African market. Discovery
announced that it is exiting this business with all remaining
covers terminated by 31 August 2024.
■ SA Distribution: provides sales and distribution services in
respect of all SA products.
■ Discovery Central Services: performing various shared
services, treasury and administrative functions to entities
within the Discovery Group.
■ Other new group initiatives: including Discovery Green, as
well as unallocated central costs.
Vitality
■ Vitality Corporate Services (VCSL): provides administration,
distribution and management services for entities within the
UK Composite.
■ Vitality Global Markets comprises Vitality Health International,
which leverages Discovery Health and Vitality’s intellectual
property to create strategic partnerships and Vitality Network
which provides a Vitality platform to international insurance
businesses. This business line also includes the equity-
accounted and Amplify Health
■ Equity-accounted interests in Ping An Health Insurance.
■ Includes Vitality AI spend, immaterial interests in equity-
accounted interests, as well as unallocated central costs.
2	1
A.1 	Segment information continued
The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/
loss from operations. Items that are excluded from normalised profit/loss from operations are separately disclosed
in the segment information to reconcile to the segment results and Group income statement. The segment
information is presented on the same basis as reported to the CODM.
The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant
with the IFRS Accounting Standards, i.e. IFRS reporting adjustments. These adjustments include the following:
(a) Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into
Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit
trusts into Discoverys results, effectively being the income and expenses relating to units held by third parties;
(b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit
adjustments; and
(c) The effects of reclassifying items to align to the IFRS Group income statement.
CHANGES EFFECTIVE FROM 1 JULY 2025
1. Effective from 1 July 2025, Discovery has revised the presentation of the ‘Intersegment funding’ charge between
SA Invest and SA Life. Previously, this charge predominantly reflected the cost incurred by SA Invest in backing its
liabilities using the assets arising from insurance contracts within SA Life. Over recent years, SA Invest has
increasingly backed its liabilities using financial assets it held directly. As a result, the ‘Intersegment funding’
charge now predominantly reflects costs associated with the service component of providing benefits on
integrated SA Life and SA Invest product offerings. To better reflect the service cost nature of this charge, the
charge has been reclassified and is now included within insurance service expense and other. The comparative
information has been restated accordingly. This change in presentation had no impact on the Group income
statement, normalised profit from operations, basic and diluted earnings, or cash flows.
A. 	Notes to the condensed consolidated financial
statements continued
21	20

-- 12 of 49 --

A.1 	Segment information continued
R million 	Notes
SA
HEALTH
SA
LIFE
SA
INVEST
SA
INSURE
SA
BANK
UK
HEALTH
UK
LIFE
ALL OTHER
SEGMENTS
SEGMENT
TOTAL
IFRS REPORTING
ADJUSTMENTS
IFRS
TOTAL
30 June 2026
Income statement
Insurance revenue 	803 	19 601 	4 796 	6 448 	– 	20 611 	9 184 	(1) 	61 442 	– 	61 442
– Contracts measured under the General measurement model/Variable fee approach 	– 	15 847 	4 796 	– 	– 	– 	9 184 	– 	29 827 	– 	29 827
– Contracts measured under Premium allocation approach 	803 	3 754 	– 	6 448 	– 	20 611 	– 	(1) 	31 615 	– 	31 615
Insurance service expenses 	(556) 	(16 059) 	(3 086) 	(5 588) 	– 	(18 046) 	(8 250) 	8 	(51 577) 	– 	(51 577)
– Claims and benefits 	(378) 	(11 576) 	(702) 	(2 923) 	– 	(11 545) 	(3 687) 	10 	(30 801) 	– 	(30 801)
– Insurance service expense and other 	(109) 	(1 987) 	(1 432) 	(1 672) 	– 	(4 328) 	(1 136) 	(2) 	(10 666) 	– 	(10 666)
– Insurance acquisition cash flows 	(69) 	(2 496) 	(952) 	(993) 	– 	(2 173) 	(3 427) 	– 	(10 110) 	– 	(10 110)
Tax specific to policyholder tax funds1 	– 	– 	(116) 	– 	– 	– 	– 	– 	(116) 	116 	–
Insurance service result (pre-reinsurance) 	247 	3 542 	1 594 	860 	– 	2 565 	934 	7 	9 749 	116 	9 865
Net (expenses)/income from reinsurance contracts 	(2) 	(606) 	– 	(117) 	– 	2 	(395) 	(6) 	(1 124) 	– 	(1 124)
– Reinsurance expense 	(3) 	(3 971) 	– 	(117) 	– 	(4) 	(9 303) 	– 	(13 398) 	– 	(13 398)
– Insurance claims recovered from reinsurers 	1 	3 365 	– 	– 	– 	6 	8 908 	(6) 	12 274 	– 	12 274
Insurance service result 	245 	2 936 	1 594 	743 	– 	2 567 	539 	1 	8 625 	116 	8 741
Net financial result from insurance finance income and expense 	– 	2 766 	(16 194) 	(20) 	– 	– 	244 	– 	(13 204) 	(91) 	(13 295)
– Net finance income/(expense) from insurance contracts 	– 	2 825 	(16 194) 	(19) 	– 	– 	648 	– 	(12 740) 	(91) 	(12 831)
– Net finance expense from reinsurance contracts 	– 	(59) 	– 	(1) 	– 	– 	(404) 	– 	(464) 	– 	(464)
Investment income using the effective interest rate method 	11 	84 	103 	322 	– 	203 	79 	27 	829 	288 	1 117
Net fair value gains on financial instruments at fair value through profit or loss 	2 	3 303 	17 497 	2 	59 	42 	– 	– 	20 905 	5 234 	26 139
Fair value adjustments to liabilities under investment contracts2 	– 	(2 810) 	(1 159) 	– 	– 	– 	– 	– 	(3 969) 	75 	(3 894)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(4 317) 	(4 317)
Net insurance and investment results 	258 	6 279 	1 841 	1 047 	59 	2 812 	862 	28 	13 186 	1 305 	14 491
Fee income from administration businesses 	A.1.1 	10 341 	228 	1 605 	– 	– 	38 	– 	2 492 	14 704 	(105) 	14 599
Vitality income 	– 	– 	– 	– 	– 	31 	298 	5 880 	6 209 	(590) 	5 619
Net banking fee and commission income 	– 	– 	– 	– 	1 815 	– 	– 	(91) 	1 724 	375 	2 099
– Banking fee and commission income 	– 	– 	– 	– 	2 763 	– 	– 	– 	2 763 	(14) 	2 749
– Banking fee and commission expense 	– 	– 	– 	– 	(948) 	– 	– 	(91) 	(1 039) 	389 	(650)
Net banking interest and similar income 	– 	– 	– 	– 	1 255 	– 	– 	– 	1 255 	1 	1 256
– Banking interest and similar income using the effective interest rate 	– 	– 	– 	– 	2 570 	– 	– 	– 	2 570 	– 	2 570
– Banking interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(1 315) 	– 	– 	– 	(1 315) 	1 	(1 314)
Other income 	A.1.1 	2 054 	193 	1 	77 	58 	– 	– 	16 062 	18 445 	(14 635) 	3 810
Non-insurance revenue and income 	12 395 	421 	1 606 	77 	3 128 	69 	298 	24 343 	42 337 	(14 954) 	27 383
Net income 	12 653 	6 700 	3 447 	1 124 	3 187 	2 881 	1 160 	24 371 	55 523 	(13 649) 	41 874
Non-insurance acquisition costs 	– 	– 	(503) 	– 	– 	– 	– 	(197) 	(700) 	364 	(336)
Expected credit losses 	– 	– 	– 	– 	(350) 	– 	– 	– 	(350) 	– 	(350)
Marketing and administration expenses 	A.1.2 	(8 023) 	(828) 	(787) 	(169) 	(2 467) 	(985) 	(377) 	(24 690) 	(38 326) 	15 751 	(22 575)
Share of net profits from equity-accounted investments 	(1) 	– 	– 	58 	– 	– 	(1) 	1 547 	1 603 	(80) 	1 523
Normalised profit/(loss) from operations 	A.2 	4 629 	5 872 	2 157 	1 013 	370 	1 896 	782 	1 031 	17 750 	2 386 	20 136
Investment income earned on shareholder investments and cash 	104 	– 	4 	12 	– 	– 	2 	166 	288 	(288) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	1 367 	1 367 	(1 367) 	–
Net fair value gains on financial assets at fair value through profit or loss 	– 	178 	48 	– 	– 	– 	– 	89 	315 	(315) 	–
Gain from dilution of equity accounted investments 	– 	– 	– 	211 	– 	– 	– 	– 	211 	50 	261
Amortisation of intangibles from business combinations 	– 	– 	– 	(30) 	– 	– 	– 	(85) 	(115) 	115 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(33) 	(33) 	33 	–
1DP Lease termination gains 	– 	– 	– 	– 	– 	– 	– 	1 463 	1 463 	(1 463) 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(1) 	(1) 	1 	–
Interest expenses on borrowings and lease liabilities 	(3) 	(1) 	– 	– 	– 	(24) 	(65) 	(1 396) 	(1 489) 	(328) 	(1 817)
Intercompany finance expenses on borrowings 	(460) 	– 	– 	– 	– 	– 	(463) 	(444) 	(1 367) 	1 367 	–
Foreign exchange losses 	– 	– 	– 	– 	– 	– 	– 	(123) 	(123) 	– 	(123)
Profit/(loss) before income tax 	4 270 	6 049 	2 209 	1 206 	370 	1 872 	256 	2 034 	18 266 	191 	18 457
Income tax expense3 	(1 138) 	(1 615) 	(1 074) 	(257) 	(152) 	(469) 	(97) 	(246) 	(5 048) 	(191) 	(5 239)
Profit/(loss) for the year 	3 132 	4 434 	1 135 	949 	218 	1 403 	159 	1 788 	13 218 	– 	13 218
Profit attributable to:
– Ordinary shareholders 	3 132 	4 434 	1 135 	949 	218 	1 403 	159 	1 702 	13 132 	– 	13 132
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	86 	86 	– 	86
– Non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–
1 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder
under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line.
2 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the
contract holder value, which is included in the fair value measurement.
3 On consolidation, the allocations referred to in items 1 and 2 above are grossed up and presented within the income tax expense line, as required by IFRS Accounting
Standards. In addition, a deferred tax asset was recognised in prior years in respect of unutilised assessed losses accumulated within the Individual Policyholder Fund
(IPF), amounting to approximately R1.6bn (net). During the period under review, the deferred tax asset began to reverse as the underlying assessed losses were utilised
and, over the medium term, will result in an increase in reported income tax expense as the asset is utilised. This increase is a non-cash item and does not give rise to
current tax payable.
A. 	Notes to the condensed consolidated financial
statements continued
22 	23
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
22

-- 13 of 49 --

A.1 	Segment information continued
R million 	Notes
SA
HEALTH
SA
LIFE
SA
INVEST
SA
INSURE
SA
BANK
UK
HEALTH
UK
LIFE
ALL OTHER
SEGMENTS
SEGMENT
TOTAL
IFRS
REPORTING
ADJUSTMENTS
IFRS
TOTAL
30 June 2025
Income statement
Insurance revenue 	518 	19 149 	4 560 	6 217 	– 	19 124 	8 050 	95 	57 713 	– 	57 713
– Contracts measured under the General measurement model/Variable fee approach 	– 	15 419 	4 560 	– 	– 	– 	8 050 	– 	28 029 	– 	28 029
– Contracts measured under Premium allocation approach 	518 	3 730 	– 	6 217 	– 	19 124 	– 	95 	29 684 	– 	29 684
Insurance service expenses 	(362) 	(15 150) 	(3 038) 	(5 499) 	– 	(17 292) 	(7 595) 	(92) 	(49 028) 	– 	(49 028)
– Claims and benefits 	(216) 	(11 375) 	(608) 	(3 000) 	– 	(11 300) 	(3 681) 	(51) 	(30 231) 	– 	(30 231)
– Insurance service expense and other 	(66) 	(1 433) 	(1 419) 	(1 597) 	– 	(3 981) 	(879) 	(37) 	(9 412) 	– 	(9 412)
– Insurance acquisition cash flows 	(80) 	(2 342) 	(1 011) 	(902) 	– 	(2 011) 	(3 035) 	(4) 	(9 385) 	– 	(9 385)
Tax specific to policyholder tax funds2 	– 	– 	(97) 	– 	– 	– 	– 	– 	(97) 	97 	–
Insurance service result (pre-reinsurance) 	156 	3 999 	1 425 	718 	– 	1 832 	455 	3 	8 588 	97 	8 685
Net (expenses)/income from reinsurance contracts 	(1) 	(1 021) 	– 	(112) 	– 	(3) 	(165) 	(4) 	(1 306) 	– 	(1 306)
– Reinsurance expense 	(2) 	(3 838) 	– 	(130) 	– 	(5) 	(8 839) 	(34) 	(12 848) 	– 	(12 848)
– Insurance claims recovered from reinsurers 	1 	2 817 	– 	18 	– 	2 	8 674 	30 	11 542 	– 	11 542
Insurance service result 	155 	2 978 	1 425 	606 	– 	1 829 	290 	(1) 	7 282 	97 	7 379
Net financial result from insurance finance income and expense 	– 	2 466 	(15 831) 	(20) 	– 	– 	417 	– 	(12 968) 	(120) 	(13 088)
– Net finance income/(expense) from insurance contracts 	– 	2 590 	(15 831) 	(20) 	– 	– 	716 	– 	(12 545) 	(120) 	(12 665)
– Net finance expense from reinsurance contracts 	– 	(124) 	– 	– 	– 	– 	(299) 	– 	(423) 	– 	(423)
Investment income using the effective interest rate method 	11 	15 	75 	268 	– 	179 	81 	17 	646 	352 	998
Net fair value gains on financial instruments at fair value through profit or loss 	29 	3 537 	17 058 	11 	52 	70 	– 	– 	20 757 	5 061 	25 818
Fair value adjustments to liabilities under investment contracts3 	– 	(2 961) 	(905) 	– 	– 	– 	– 	– 	(3 866) 	56 	(3 810)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(4 394) 	(4 394)
Other losses on financial instruments 	– 	– 	– 	– 	(9) 	– 	– 	– 	(9) 	– 	(9)
Net insurance and investment results 	195 	6 035 	1 822 	865 	43 	2 078 	788 	16 	11 842 	1 052 	12 894
Fee income from administration businesses 	A.1.1 	9 766 	188 	1 260 	– 	– 	35 	– 	3 185 	14 434 	(108) 	14 326
Vitality income 	A.1.1 	– 	– 	– 	– 	– 	31 	267 	5 575 	5 873 	(551) 	5 322
Net banking fee and commission income 	– 	– 	– 	– 	1 373 	– 	– 	(77) 	1 296 	399 	1 695
– Banking fee and commission income 	– 	– 	– 	– 	2 238 	– 	– 	– 	2 238 	– 	2 238
– Banking fee and commission expense 	– 	– 	– 	– 	(865) 	– 	– 	(77) 	(942) 	399 	(543)
Net banking interest and similar income 	– 	– 	– 	– 	965 	– 	– 	– 	965 	1 	966
– Banking interest and similar income using the effective interest rate 	– 	– 	– 	– 	2 203 	– 	– 	– 	2 203 	– 	2 203
– Banking interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(1 238) 	– 	– 	– 	(1 238) 	1 	(1 237)
Other income 	A.1.1 	1 838 	119 	1 	79 	69 	19 	– 	14 591 	16 716 	(14 884) 	1 832
Non-insurance revenue and income 	11 604 	307 	1 261 	79 	2 407 	85 	267 	23 274 	39 284 	(15 143) 	24 141
Net income 	11 799 	6 342 	3 083 	944 	2 450 	2 163 	1 055 	23 290 	51 126 	(14 091) 	37 035
Non-insurance acquisition costs 	– 	– 	(395) 	– 	– 	– 	– 	(294) 	(689) 	305 	(384)
Expected credit losses 	– 	– 	– 	– 	(279) 	– 	– 	– 	(279) 	– 	(279)
Marketing and administration expenses 	A.1.2 	(7 540) 	(817) 	(701) 	(213) 	(2 239) 	(975) 	(424) 	(23 305) 	(36 214) 	14 449 	(21 765)
Share of net profits from equity-accounted investments 	– 	– 	– 	86 	– 	– 	6 	1 174 	1 266 	(51) 	1 215
Normalised profit/(loss) from operations 	A.2 	4 259 	5 525 	1 987 	817 	(68) 	1 188 	637 	865 	15 210 	612 	15 822
Investment income earned on shareholder investments and cash 	98 	31 	13 	7 	– 	– 	– 	203 	352 	(352) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	1 351 	1 351 	(1 351) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	51 	54 	– 	– 	– 	– 	– 	105 	(105) 	–
Loss from dilution of equity accounted investments 	– 	– 	– 	(32) 	– 	– 	– 	– 	(32) 	– 	(32)
Impairment of goodwill 	(20) 	– 	– 	– 	– 	– 	– 	– 	(20) 	– 	(20)
Amortisation of intangibles from business combinations 	– 	– 	– 	(51) 	– 	– 	– 	(71) 	(122) 	122 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(72) 	(72) 	72 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(80) 	(80) 	80 	–
Interest expenses on borrowings and lease liabilities 	(2) 	(1) 	– 	– 	– 	(18) 	(201) 	(1 588) 	(1 810) 	(277) 	(2 087)
Intercompany finance expenses on borrowings 	(447) 	– 	– 	– 	– 	– 	(444) 	(460) 	(1 351) 	1 351 	–
Foreign exchange (losses)/gains 	(5) 	(14) 	(5) 	– 	– 	– 	1 	(13) 	(36) 	– 	(36)
Profit/(loss) before income tax 	3 883 	5 592 	2 049 	741 	(68) 	1 170 	(7) 	135 	13 495 	152 	13 647
Income tax expense 4 	(1 046) 	(1 508) 	(793) 	(216) 	25 	(311) 	(62) 	(26) 	(3 937) 	(152) 	(4 089)
Profit/(loss) for the year 	2 837 	4 084 	1 256 	525 	(43) 	859 	(69) 	109 	9 558 	– 	9 558
Profit attributable to: 	–
– Ordinary shareholders 	2 843 	4 084 	1 256 	525 	(43) 	859 	(69) 	16 	9 471 	– 	9 471
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	93 	93 	– 	93
– Non-controlling interest 	(6) 	– 	– 	– 	– 	– 	– 	– 	(6) 	– 	(6)
1 The comparative information has been restated due to those changes noted in items 1as discussed in the introduction to Segment information in section A.1.
2 Tax specific to policyholder tax funds is reallocated from the income tax expense line. This includes taxes that are directly chargeable to the policyholder
under insurance contracts, with a corresponding change in the policyholder fund values, which are included within the insurance revenue line.
3 The value is reflected net of contract holder taxes, which are taxes directly chargeable to the contract holder. There is a corresponding change in the
contract holder value, which is included in the fair value measurement.
4 On consolidation, the allocations referred to in items 1 and 2 above are grossed up and presented within the income tax expense line, as required by IFRS Accounting
Standards. In addition, a deferred tax asset was recognised in prior years in respect of unutilised assessed losses accumulated within the Individual Policyholder Fund
(IPF), amounting to approximately R1.6bn (net). During the period under review, the deferred tax asset began to reverse as the underlying assessed losses were utilised
and, over the medium term, will result in an increase in reported income tax expense as the asset is utilised. This increase is a non-cash item and does not give rise to
current tax payable.
A. 	Notes to the condensed consolidated financial
statements continued
24 	25
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
24

-- 14 of 49 --

A.1 	Segment information continued
A.1.1 	REVENUES AND INCOME WITH OTHER OPERATING SEGMENTS
The net income presented within each respective segment includes the following items of revenue and income
derived from transactions with other operating segments of the Group:
R million
SA
HEALTH
SA
LIFE
SA
INVEST
SA
INSURE
SA
BANK
UK
HEALTH
UK
LIFE
ALL OTHER
SEGMENTS
SEGMENT
TOTAL
30 June 2026
Fee income from administration businesses 	– 	– 	– 	– 	– 	– 	– 	91 	91
Vitality income 	– 	– 	– 	– 	– 	– 	– 	590 	590
Other income 	249 	169 	1 	52 	58 	93 	– 	15 991 	16 613
Total 	249 	169 	1 	52 	58 	93 	– 	16 672 	17 294
30 June 2025
Fee income from administration businesses 	– 	– 	– 	– 	– 	– 	– 	94 	94
Vitality income 	– 	– 	– 	– 	– 	– 	– 	551 	551
Other income 	235 	130 	1 	64 	69 	94 	– 	14 784 	15 377
Total 	235 	130 	1 	64 	69 	94 	– 	15 429 	16 022
A.1.2 	MATERIAL ITEMS OF EXPENSES
Additional information on material items of expenses included within the marketing and administration expenses:
R million
SA
HEALTH
SA
LIFE
SA
INVEST
SA
INSURE
SA
BANK
UK
HEALTH
UK
LIFE
ALL OTHER
SEGMENTS
SEGMENT
TOTAL
30 June 2026
Depreciation and amortisation 	(191) 	(2) 	(33) 	(5) 	(332) 	– 	(58) 	(1 330) 	(1 951)
Derecognition of intangible assets and property and equipment 	– 	– 	– 	(7) 	– 	– 	(6) 	(36) 	(49)
Impairment of intangible assets and property and equipment 	– 	– 	– 	(12) 	– 	– 	– 	(94) 	(106)
Staff costs 	(3 076) 	(286) 	(272) 	(78) 	(1 092) 	– 	– 	(8 796) 	(13 600)
Other expenses1 	(4 756) 	(540) 	(482) 	(67) 	(1 043) 	(985) 	(313) 	(14 434) 	(22 620)
Total: Marketing and administration expenses 	(8 023) 	(828) 	(787) 	(169) 	(2 467) 	(985) 	(377) 	(24 690) 	(38 326)
30 June 2025
Depreciation and amortisation 	(174) 	(1) 	(24) 	(1) 	(368) 	– 	(58) 	(1 273) 	(1 899)
Derecognition of intangible assets and property and equipment 	– 	(43) 	– 	(52) 	– 	– 	(1) 	(45) 	(141)
Impairment of intangible assets and property and equipment 	(20) 	(28) 	– 	(18) 	– 	(79) 	– 	– 	(145)
Staff costs 	(3 038) 	(284) 	(262) 	(95) 	(984) 	– 	– 	(8 062) 	(12 725)
Other expenses1 	(4 308) 	(461) 	(415) 	(47) 	(887) 	(896) 	(365) 	(13 925) 	(21 304)
Total: Marketing and administration expenses 	(7 540) 	(817) 	(701) 	(213) 	(2 239) 	(975) 	(424) 	(23 305) 	(36 214)
1 Included in SA Health other expenses are IT systems and consumables of R1 756 million (2025: R1 576 million).
A. 	Notes to the condensed consolidated financial
statements continued
26 	27
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
26

-- 15 of 49 --

A.2 	Normalised profit from operations
The following table shows the main components of the normalised profit from operations for the year ended
30 June 2026:
R million
Group
2026
Group
2025 	% Change
Discovery Health 	4 629 	4 259 	9 %
Discovery Life 	5 872 	5 525 	6 %
Discovery Invest 	2 157 	1 987 	9 %
Discovery Insure - Personal lines 	1 013 	817 	24 %
Discovery Bank 	370 	(68) 	(644)%
Other initiatives and central costs1 	(173) 	(515) 	(66)%
Normalised profit from Discovery SA 	13 868 	12 005 	16 %
VitalityHealth 	1 896 	1 188 	60 %
VitalityLife 	782 	637 	23 %
Ping An Health Insurance1 	1 317 	1 206 	9 %
Vitality Global Markets2 	186 	263 	(29)%
Vitality AI1,3 	(299) 	(89) 	236 %
Normalised profit from Vitality 	3 882 	3 205 	21 %
Normalised profit from operations 	17 750 	15 210 	17 %
1 Presented in ‘All other segments’ on the Segment information disclosure note in section A.1.
2 Comparative information has been re-presented to combine Vitality Health International – Other (2025: loss R291 million) and Vitality Network (2025:
R554 million) into Vitality Global Markets to align with the way management monitors and assesses the performance of the Vitality operations.
3 Vitality AI also includes other central costs of R56 million (2025: R89 million).
A.3 	Earnings, headline earnings and normalised headline earnings
Group
2026
Group
2025
Number of shares used in calculation
Weighted number of shares in issue ('000) 	671 104 	665 168
Diluted weighted number of shares ('000) 	675 000 	668 715
Earnings per share (cents):
– basic 	1 936.7 	1 402.2
– diluted 	1 925.5 	1 394.9
Headline earnings per share (cents):
– basic 	1 925.6 	1 447.0
– diluted 	1 914.5 	1 439.4
Normalised headline earnings per share (cents):
– basic 	1 757.6 	1 470.4
– diluted 	1 747.4 	1 462.8
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (‘000)
Issued ordinary shares at 1 July 	666 587 	661 021
Effect of shares options exercised and vesting of shares awards 	4 517 	4 147
Weighted-average number of ordinary shares at 30 June (basic) 	671 104 	665 168
Effect of share options exercised and vesting of share awards 	3 896 	3 547
Weighted-average number of ordinary shares at 30 June (diluted) 	675 000 	668 715
EARNINGS RECONCILIATION (R MILLION)
Profit attributable to the ordinary shareholders 	13 132 	9 471
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan 	(135) 	(144)
Basic earnings attributable to ordinary shareholders 	12 997 	9 327
A. 	Notes to the condensed consolidated financial
statements continued
28
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
A.3 	Earnings, headline earnings and normalised headline earnings
continued
Headline earnings reconciliation
Headline earnings per share is disclosed per the JSE Listings Requirements and is calculated in accordance with the
circular titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is
based on the net profit after tax attributable to ordinary shareholders adjusted for items of a capital nature and the
weighted average number of ordinary shares in issue.
Group 2026 	Group 2025
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Basic earnings attributable to ordinary
shareholders 	12 997 	9 327
Adjusted for:
IFRS 3: Goodwill impairment 	– 	– 	– 	20 	– 	20
IFRS 5: Impairment - Non-current asset
held for sale change of intention 	– 	– 	– 	79 	– 	79
IAS 38: Impairment of intangible assets 	106 	(27) 	79 	65 	(10) 	55
IAS 16: Gain on disposal of property and
equipment 	(1) 	* 	(1) 	(1) 	* 	(1)
IAS 16: Loss on derecognition of property
and equipment 	23 	(6) 	17 	11 	(3) 	8
IAS 38: Loss on derecognition of intangible
assets 	68 	(15) 	53 	131 	(19) 	112
IAS 28: (Gains)/losses on the dilution and
disposal of equity-accounted investments 	(261) 	39 	(222) 	32 	(7) 	25
Headline earnings
(basic and diluted) 	12 923 	9 625
* Amount is less than R500 000.
Normalised headline earnings reconciliation
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in note E.2.
Management considers that Normalised headline earnings is an appropriate alternative performance measure to
enhance the comparability and understanding of the financial performance of the Group.
Group 2026 	Group 2025
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	12 923 	9 625
Adjusted for:
– Amortisation of intangible assets arising
from business combinations 	85 	(21) 	64 	71 	(18) 	53
– Restructuring costs 	1 	– 	1 	80 	(19) 	61
– Gain arising from the initial recognition
of deferred tax assets resulting from
prior period assessed losses, net of
related adjustments 	– 	(205) 	(205) 	– 	(9) 	(9)
– 1DP Lease termination gains 	(1 463) 	395 	(1 068) 	– 	– 	–
Adjustments attributable to equity-accounted
investments:
– Amortisation of intangible assets arising
from business combinations 	30 	– 	30 	51 	– 	51
– CMT disposal related transaction costs 	50 	– 	50 	– 	– 	–
Normalised headline earnings (basic
and diluted) 	11 795 	9 781
A. 	Notes to the condensed consolidated financial
statements continued
29	28

-- 16 of 49 --

A.4 	Revenue from non-insurance activities
Discovery Group’s Revenue includes ‘Fee income from administration businesses’, ‘Vitality income’ and ‘Banking fee
and commission income’.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1 Segment information.
The split of revenue according to the timing of satisfaction of performance obligations, i.e. ‘over time’ or a ‘point-in-
time’ is as follows:
R million
Group
2026
Group
20251
R million 	2026 	20251
Fee income from administration business 	14 599 	14 326
– Over time 	14 508 	13 769
– Point-in-time 	91 	557
Vitality income 	5 619 	5 322
– Over time 	4 018 	3 671
– Point-in-time 	1 601 	1 651
Banking fee and commission income 	2 749 	2 238
– Over time 	984 	783
– Point-in-time 	1 765 	1 455
1 Banking fee and commission income has been reclassified. For the year ended 30 June 2025, monthly account fees of R783 million, recognised over time,
were inadvertently classified as point-in-time revenue, while interchange and transaction fees of R1 455 million, recognised at a point in time, were
inadvertently classified as over-time revenue. The total Banking fee and commission income of R2 238 million was unaffected. This classification error has
been corrected, and the comparative period has been restated accordingly.
A.5 	Borrowings at amortised cost
Group
2026
Group
2025	R million 	Reference
Borrowings from banks 	A.5.1 	17 787 	16 103
Lease liabilities 	905 	3 941
Bank overdraft 	– 	2
Balance at end of the year 	18 692 	20 046
Current 	5 261 	7 452
Non-current 	13 431 	12 594
Balance at end of the year 	18 692 	20 046
A.5.1 	BORROWINGS FROM BANKS
Discovery continues to maintain strong access to funding markets. During the period, favourable market conditions
and sustained investor demand for Discovery debt instruments provided an opportunity to optimise its funding
structure. The initiatives undertaken enhanced funding efficiency, lowered financing costs by approximately
R200 million, and further aligned the debt profile with Discovery’s underlying operational and currency exposures.
Key actions included refinancing UK borrowings through Rand-denominated funding at attractive rates, supported by
cross-currency basis swaps to manage foreign exchange and interest rate exposures; issuing redeemable preference
shares to support capital deployment within the UK operations; and arranging a specific funding facility for the
acquisition of 1 Discovery Place (Discovery's head office building in Sandton, South Africa) as well as entering into
related interest rate hedging strategies.
Credit rating
In November 2024 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer
rating of Ba3 and upgraded the national-scale long-term issuer rating to Aa3.za from A1.za. The outlook remained
unchanged as stable, aligned to the outlook of the country.
A. 	Notes to the condensed consolidated financial
statements continued
30
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
1
A.5 	Borrowings at amortised cost continued
A.5.1 	BORROWINGS FROM BANKS continued
Group
20261
Group
2025
R million 	Reference
Weighted
average funding
rate2
Carrying
amount
Facility
value
Carrying
amount
Facility
value
SA Borrowings 	17 324 	18 296 – 	12 393 	12 674
Fixed interest rate loan facilities 	2 758 	3 197 – 	3 757 	4 104
– Unsecured: Other3 	9.21% 	2 758 	3 197 	1 707 	2 050
– Unsecured: DMTN 	– 	– 	2 050 	2 054
Floating interest rate with floating-to-fixed
interest rate swap 	9 947 	9 905 – 	6 821 	6 768
– Unsecured: Other 	– 	– 	1 500 	1 500
– Unsecured: DMTN4 	8.03% 	6 823 	6 768 	5 321 	5 268
– Secured: Other4 	(i) 	7.22% 	3 124 	3 137 	– 	–
Floating interest rate 	4 619 	5 194 – 	1 815 	1 802
– Unsecured: Other4 	8.41% 	1 507 	1 500 	694 	691
– Unsecured: DMTN4 	7.84% 	2 710 	2 694 	1 121 	1 111
– Secured: Other4 	(i) 	8.08% 	402 	1 000 	– 	–
UK Borrowings 	463 	1 195 	3 710 	3 773
Floating interest rate 	463 	1 195 – 	3 710 	3 773
– Unsecured: Other 	(ii) 	6.58% 	463 	1 195 	3 710 	3 773
Total borrowings (Refer to note A.5) 	17 787 	19 491 – 	16 103 	16 447
1 The borrowings note has been redesigned in this financial year to enhance the presentation of the Group's funding arrangements and related risk exposures.
Comparative information has been re-presented on a consistent basis.
2 The weighted average annual interest rate has been calculated by weighting the all-in rate (or hedged rate where hedge accounting was applied) by facility
value at the reporting date.
3 Includes Redeemable Preference shares issued of R1.2 billion.
4 Included in the weighted average rate are JIBAR linked interest rates.
i. 	During June 2026, Discovery finalised the acquisition of Phase 1 of 1 Discovery Place (1DP), which was fully funded
through bank borrowings. The increase in the Borrowings from banks was offset by the termination of the leases
of Phase 1 and Phase 2 of 1 Discovery Place (1DP), which resulted in the derecognition of the related lease
liabilities also presented within Borrowings at amortised cost.
ii. In October 2025, the Group settled £100 million of UK borrowings ahead of their contractual maturity in
December 2025. The settlement was funded through a drawdown of R1.5 billion under the Group’s existing
revolving credit facility, together with additional South African borrowings to fund the remaining balance. The
refinancing was executed through an intercompany loan arrangement, with the associated foreign exchange and
interest rate exposures managed through a cross-currency basis swap.
Total finance costs in respect of the UK borrowings for the year ended 30 June 2026 was £5.07 million (R117 million)
(2025: £12.14 million (R285 million)).
Total finance costs in respect of South African borrowings and related hedges for the year ended 30 June 2026 was
R1 227 million (2025: R1 261 million).
A. 	Notes to the condensed consolidated financial
statements continued
31	30

-- 17 of 49 --

A.6 	Fair value hierarchy
The Group’s assets and liabilities measured at fair value are disclosed in accordance with the fair value hierarchy. The
hierarchy has three levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes those assets and liabilities that are measured using unadjusted, quoted prices in an active market
for identical financial instruments. Quoted prices are readily and regularly available from an exchange, dealer,
broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly
occurring market transactions on an arm’s length basis.
Level 2: includes those assets and liabilities that are valued using techniques based significantly on observable
market data. Assets and liabilities in this category are valued using:
(a) Quoted prices for similar instruments or identical instruments in markets that are not considered to be active; or
(b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly
based on observable market data.
Level 3: includes those assets and liabilities that are valued using valuation techniques that incorporate information
other than observable market data and where at least one input (which could have a significant effect on the
instruments’ valuation) cannot be based on observable market data.
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2026
Financial assets
Financial instruments mandatorily at fair value through
profit or loss: 	177 449 	45 435 	– 	222 884
– Equity portfolios 	115 151 	18 236 	– 	133 387
– Debt portfolios 	62 084 	1 311 	– 	63 395
– Money market portfolios 	– 	11 664 	– 	11 664
– Multi-asset portfolios 	214 	14 224 	– 	14 438
Derivative financial instruments at fair value: 	– 	147 	– 	147
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	146 	– 	146
Cash and cash equivalents 	– 	26 	– 	26
Total financial assets 	177 449 	45 608 	– 	223 057
Financial liabilities
Third-party interest in consolidated funds 	– 	40 901 	– 	40 901
Investment contracts at fair value through profit or loss 	– 	38 614 	– 	38 614
Derivative financial instruments at fair value: 	– 	117 	– 	117
– used as cash flow hedges 	– 	79 	– 	79
– not designated as hedging instruments 	– 	38 	– 	38
Total financial liabilities 	– 	79 632 	– 	79 632
There were no transfers between hierarchy levels during the current financial period.
A. 	Notes to the condensed consolidated financial
statements continued
32
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
A.6 	Fair value hierarchy continued
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2025
Financial assets
Financial instruments mandatorily at fair value through
profit or loss: 	141 140 	52 636 	– 	193 776
– Equity portfolios 	87 458 	12 477 	– 	99 935
– Debt portfolios 	53 682 	2 186 	– 	55 868
– Money market portfolios 	– 	12 948 	– 	12 948
– Multi-asset portfolios 	– 	25 025 	– 	25 025
Financial instruments at fair value through other
comprehensive income: 	– 	– 	14 	14
– Equity portfolios 	– 	– 	14 	14
Derivative financial instruments at fair value: 	– 	41 	22 	63
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	40 	22 	62
Total financial assets 	141 140 	52 677 	36 	193 853
Non-financial assets
Non-current asset held for sale1 	– 	– 	62 	62
Total assets 	141 140 	52 677 	98 	193 915
Financial liabilities
Third-party interest in consolidated funds 	– 	35 932 	– 	35 932
Investment contracts at fair value through profit or loss 	– 	32 188 	– 	32 188
Derivative financial instruments at fair value: 	– 	135 	– 	135
– used as cash flow hedges 	– 	117 	– 	117
– not designated as hedging instruments 	– 	18 	– 	18
Total financial liabilities 	– 	68 255 	– 	68 255
1 The fair value was determined from an agreed sales price between unrelated parties, reflecting an arm’s length transaction under current market conditions.
Given the agreed sales price, no variability is expected in the fair value measurement, as the transaction price represents the best available estimate of fair
value. The measurement approach incorporates relevant observable market inputs where available.
A. 	Notes to the condensed consolidated financial
statements continued
33	32

-- 18 of 49 --

A.6 	Fair value hierarchy continued
SPECIFIC VALUATION TECHNIQUES USED TO VALUE FINANCIAL INSTRUMENTS IN
LEVEL 2 AND LEVEL 3
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange-traded
financial instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques
including the use of recent arm’s-length market transactions, reference to the current fair value of another
instrument that is substantially the same, discounted cash flow techniques, option pricing models or other valuation
techniques that provide a reliable estimate of prices obtained in actual market transactions.
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique
Main inputs and
assumptions for level 2
fair value hierarchy
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity linked
investments is made by the provider of the note. Discovery has
procedures in place to ensure that these prices are correct. Aside
from the daily reasonableness checks versus similar funds and
movement since the prior day’s price, the fund values are
calculated with reference to a specific formula or index,
disclosed to the policyholders, which is recalculated by Discovery
to check if the price provided by the provider is correct.
– discount rate
– spot prices of the
underlying
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future
cash flows using a risk-adjusted discount rate.
– discount rate, credit
spread
Multi-assets 	The fair values are determined using the quoted put (exit) price
provided by the fund manager and discounted for the applicable
notice period. The fair value of a financial liability with a demand
feature is not less than the amount payable on demand,
discounted from the first date on which the amount could be
required to be paid.
– discount rate
Investment
contracts at
fair value,
including third-
party interest
in consolidated
funds
Unit-linked policies: assets which are linked to the investment
contract liabilities are owned by the Group. The investment
contract obliges the Group to use these assets to settle these
liabilities. Therefore, the fair value of third-party interest in
consolidated funds and investment contract liabilities is
determined with reference to the fair value of the underlying
assets (meaning, amount payable on surrender of the policies).
Annuity certain: discounted cash flow models are used to
determine the fair value of the stream of future payments.
– discount rate
– spot price of underlying
Derivatives 	Standard derivative contracts are valued using market accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
– Discounted cash flow model
– Black-Scholes model
– Combination technique models
– discount rate
– spot prices of the
underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples
Unlisted equity
instrument at
fair value
For unlisted equity instruments, a discounted cash flow
methodology is used. The discounted cash flow methodology
values an asset by determining the present value of its expected
future net cash flows. This valuation considers both historic
experience and future projected budgets. The valuation is stress
tested by considering earnings multiples, e.g., price-earnings
multiple (P/E ratio).
– discount rate
– growth rate
– projected earnings
– valuation
– multiples, eg, P/E ratio
A. 	Notes to the condensed consolidated financial
statements continued
34
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
35
BOther significant items
in these results
36 B.1 	Exchange rates to South African Rand
used in the preparation of these
results
36 B.2 	Capital management, financial
leverage ratio and covenants
38 B.3.1 Impact of financial risk variances
within the SA Life and UK Life
operating segments
39 B.3.2 Purchase of Discovery's South African
Head office building, 1 Discovery
Place (1DP)
39 B.3.3 Partial disposal of interest in
Cambridge Mobile Telematics
Incorporated (CMT)
40 B.4 	Cash and cash equivalents
41 B.5 	Consolidation of Discovery Unit Trusts
41 B.6 	Changes in directorate
42 B.7 	Events after reporting date and
dividend declaration in respect of the
year ended 30 June 2026
34

-- 19 of 49 --

B.1 	Exchange rates to the South African rand used in the preparation of
these results
Closing rates 	Average rates
Exchange rate to SA rand
Group
2026
Group
2025
Group
2026
Group
2025
US dollar 	16.37 	17.77 	16.90 	18.16
Pound sterling 	21.73 	24.34 	22.68 	23.48
Chinese yuan 	2.41 	2.48 	2.42 	2.51
B.2 	Capital management, financial leverage ratio and covenants
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group
statement of financial position. The Group’s objectives when managing capital are:
■ To comply with the statutory capital and liquidity requirements in each of its regulated entities;
■ To maintain a capital and liquidity buffer in excess of the statutory requirements in order to reduce the risk of
breaching the statutory requirements;
■ To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
■ To achieve an optimal and efficient capital funding profile; and
■ To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between
the centre and subsidiaries within South Africa, UK and US. The committee is the governance body for all capital
allocation activities across the Group ultimately overseen by the Board.
A range of capital-raising options are available to manage the capital structure of the Group, which includes the issue
of new shares, debt, financial reinsurance arrangements and other hybrid instruments.
REGULATORY CAPITAL
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies
the minimum amount and type of capital that must be held by each of the subsidiaries in addition to their insurance
liabilities. The minimum required capital must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related
Prudential Standards, while VitalityHealth and VitalityLife are regulated under the Solvency UK regulatory regime.
The table below summarises the capital requirements of insurance companies on a statutory basis, across the Group
subsidiaries, and the actual solvency capital held in relation to these requirements as at the end of the reporting
period.
2026 	2025
Solvency capital
requirements 	Cover
Solvency capital
requirements 	Cover
Discovery Life 	R29 951 million 	1.7 times 	R23 479 million 	1.9 times
Discovery Insure 	R1 273 million 	2.1 times 	R1 112 million 	2.1 times
VitalityHealth 	£127 million
1.9 times
£126 million
1.8 times	(R2 754 million) 	(R3 072 million)
VitalityLife 	£451 million
1.9 times
£383 million
2.0 times	(R9 807 million) 	(R9 322 million)
Discovery Bank’s common equity tier 1 (CET1) ratio is 16.29 % (2025: 16.31%). In addition, the Bank holds an internal
management buffer to cater for future unexpected growth and volatility in risk weighted exposures, as well as an
estimation risk buffer.
B. 	Other significant items in these results
36
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
B.2 	Capital management, financial leverage ratio and covenants continued
As part of the capital management process, the Group monitors its capital structure in line with a Financial Leverage
Ratio (FLR) risk appetite. The Group’s strategy is to maintain a prudent FLR in line with Discovery’s risk appetite
statement, with an overall maximum FLR of 28%, which remains conservative.
The FLR is calculated as follows: total debt1 ÷ (total debt + total equity + 50% Contractual Service Margin (CSM) net of
reinsurance and net of tax). Non-recourse financial reinsurance and all IFRS 16 lease liabilities are not included in the
measurement of total debt.
R million 	Group 2026 	Group 2025
Borrowings at amortised cost, excluding lease liabilities (refer to note A.5.1) 	17 787 	16 105
Total debt 	17 787 	16 105
Total equity 	82 661 	65 699
Total Contractual Service Margin (CSM)2 	29 393 	28 047
Financial leverage ratio % (50% CSM factored in)1 	15.4% 	16.8%
1 If the borrowings for 1 Discovery Place are excluded, the total debt would be R14 261million and the Finance leverage ratio would be 12.8%.
2 The CSM is net of reinsurance and net of tax.
The FLR at 30 June 2026 is within Discovery’s risk appetite.
DEBT COVENANTS
The information presented in the table below relating to the Embedded Value and Solvency Capital Requirement is
unaudited. The following are the key debt covenants and their proximity to minimum requirements as per the
contractual financial covenants.
Debt Covenant and explanation 	Minimum requirement
Unaudited
Group
2026
Unaudited
Group
2025
Group Debt1 to EBITDA2 Ratio: 	Less than 2.5 times 	0.91 times 	1.02 times
Group financial indebtedness to embedded
value3
Less than 30% of Group
Embedded value
13.1 % 	13.3 %
Discovery Life Solvency Capital Requirement
(SCR) Cover
SCR cover must be more
than 1.1
1.7 times 	1.9 times
Group embedded value 	Greater than R30 billion 	R142 924 million 	R126 554 million
New business embedded value must not be
negative
Positive value of new
business for 3 consecutive
6-month periods
June 2026:
R1 465 million
December 2025:
R1 356 million
June 2025:
R1 201 million
June 2025:
R1 201 million
December 2024:
R953 million
June 2024:
R1 148 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the
1 Discovery Place (Discovery head office building in Sandton, South Africa) lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1 Discovery Place and excludes items
deemed extraordinary and specified Financial Reinsurance (FinRe) arrangements.
3 Group financial indebtedness is as per Group Debt in the calculation.
B. 	Other significant items in these results continued
37	36

-- 20 of 49 --

B.3.1 Impact of market rate changes within the SA Life and UK Life
operating segments
The actuarial bases of Discovery Life and VitalityLife are actively maintained to ensure that the most up-to-date best
estimate view of future expectations is reflected. Under IFRS 17, financial risk assumptions are updated to reflect
current market prices at the reporting date and remain in place until the next reporting date. These assumptions also
affect insurance finance income and expense (IFIE) for the following reporting period.
Discovery has elected, as permitted under IFRS 17 Insurance Contracts, to recognise the valuation date impact of
changes in financial risk at the reporting date in Other Comprehensive Income (OCI) for specified portfolios.
Consequently, changes in financial risk, comprising changes in discount rates, inflation and foreign currency, do not
directly affect the Group income statement as a result of this election. Instead, the effect of changes in financial risk
during the period is recognised within net IFIE from insurance contracts issued and reinsurance contracts held in OCI,
with the cumulative effect presented in the Insurance Finance Reserve within equity.
During the financial year ended 30 June 2026:
■ A significant reduction in long-term government bond yield curves in South Africa (c. 285 bps in the weighted
average nominal rate and c. 145 bps in the weighted average real rate) resulted in net gains recognised in OCI,
thereby improving the Insurance Finance Reserve for Discovery Life. The gain is net of the negative impact of lower
implied inflation rates.
■ An increase in government bond yield curves in the United Kingdom (c. 20 bps in the weighted average nominal
rate and c. 7 bps increase in the weighted average real rate) resulted in gains recognised in OCI, thereby improving
the Insurance Finance Reserve for VitalityLife. The VitalityLife own license portfolio benefitted from a favourable
inflation movement, which was partly offset by an unfavourable interest rate movement. For the portfolios still
held on the Prudential Assurance Company Limited (PAC) license, the interest rate impact was greater than the
inflation impact, resulting in a net favourable impact.
The balance of the Insurance Finance Reserve will effectively be reclassified to profit or loss using a constant rate
over the remaining life of each relevant group of contracts. As a result, the reserve is expected to unwind to zero over
the remaining lifetime of the contracts. The OCI election reduces the income statement volatility that would
otherwise arise from changes in interest rates, as IFRS 17 requires IFIE to be recognised using a constant rate over
time.
Changes in the implied inflation assumption, that is extrapolated from the differential in prevailing market yield
curves , affect the long-term best estimate cash flows. These impacts are also recognised over the life of the
contracts. They therefore change the IFIE recognised in the period, compared with the amount that would have been
recognised before the update to the best estimate cash flow assumptions.
Under IFRS 17, IFIE is a material driver of earnings and is determined using the interest rate curves at the start of the
financial year. The reduction in implied future long-term inflation is expected to reduce Discovery Group's FY2027
systematic accretion through IFIE by c. R650 million, all else being equal.
A summary of the movements in the Insurance Finance Reserve, net of reinsurance and net of tax, for the respective
portfolios during the period is set out below.
INSURANCE FINANCE RESERVE (IFR)
R million
Accumulated comprehensive (income)/expenses
within IFR
SA Life Risk
(GMM)
SA Life:
Group Life and
Other (PAA)
UK Life Risk
(GMM) 	Total
Balance at beginning of the period 	5 938 	(262) 	(2 748) 	2 928
Effects of changes in financial risk 	(8 113) 	268 	(572) 	(8 417)
Balance at end of the period 	(2 175) 	6 	(3 320) 	(5 489)
B. 	Other significant items in these results continued
38
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
B.3.2 Purchase of Discovery's South African Head office building,
1 Discovery Place (1DP)
During June 2026, Discovery finalised the acquisition of Phase 1 of 1DP, comprising the Grove and Park buildings, and
cancelled the remaining period of the long-term lease for Phase 2, comprising the Ridge building. The transaction
was announced on SENS on 6 February 2026.
The acquisition was facilitated through Discovery Propco (Pty) Limited, a wholly owned subsidiary of Discovery
Limited. The total consideration for the transaction was R4.05 billion, exclusive of VAT, and was fully funded through
pre-arranged debt.
At the date of the transaction becoming effective, Discovery Group:
■ Derecognised the right-of-use assets and lease liabilities relating to 1DP, including Phases 1 and 2, resulting in a net
gain from the early termination of the lease of c.R1.6 billion before tax. Discovery excluded this gain on termination
of the leases, net of related expenses, from normalised profit from operations and normalised headline earnings.
■ Recognised the acquired land and buildings as “owner occupied” for purposes of the Group’s consolidated financial
statements, together with external borrowings of c.R4 billion.
As explained at the time of the announcement, the transaction resulted in an initial increase in the FLR as debt was
raised specifically to fund the property acquisition. However, the transaction is effectively self-funding compared to
the previous lease obligations and has immediate cash flow benefit to the Group. It is still expected that the Group’s
FLR will reduce towards the lower end of the Group's guidance range of 10% to 20% over the next few years.
B.3.3 Partial disposal of interest in Cambridge Mobile Telematics
Incorporated (CMT)
As announced on SENS on 24 March 2026, Discovery, through its wholly owned subsidiary, Vitality Group
International Incorporated (VGI), disposed of approximately half of its remaining interest in Cambridge Mobile
Telematics Incorporated (CMT). Before the disposal, Discovery held an 8.7% shareholding in CMT.
Discovery originally invested US$5 million in 2014 to acquire a 21.67% interest in CMT, which has been both an
associate investment and a strategic partner to Discovery Insure, providing leading expertise in the telematics
environment. Since the original investment, various capital injections by other investing parties and corporate actions
have resulted in net dilution and disposal gains for Discovery of US$75 million in aggregate, which have been
recognised outside of normalised profit from operations and headline earnings over time. This included a partial sell-
down in 2019, for which Discovery received US$28.5 million in cash proceeds.
Following an offer from TPG Global LLC, VGI disposed of 49.4% of its total shareholding in CMT and received gross
cash proceeds of US$49.5 million, equivalent to c.R831 million. The strategic partnership is expected to remain largely
unaffected by the reduction in the Group’s shareholding and Discovery will continue to account for the investment as
an associate as a result of its contractual strategic rights and ongoing involvement. The disposal crystallised the
equity-accounted earnings attributable to the disposed portion to date, as well as an additional gain on the partial
disposal of an interest in an associate of $10.1 million, equivalent to c.R169 million, net of attributable costs, tax as
well as the reclassification of related foreign currency translation reserves. The gain on disposal is excluded from
normalised operating profit, headline earnings (exclusive of specified costs) and normalised headline earnings.
B. 	Other significant items in these results continued
39	38

-- 21 of 49 --

B.4 	Cash and cash equivalents
B.4.1 	GROUP STATEMENT OF CASH FLOWS
R million
Group
2026
Group
2025
Cash flows from operating activities 	7 036 	8 667
Cash flows from investing activities 	(4 798) 	(1 823)
Cash flows from financing activities 	(538) 	(4 016)
Net increase in cash and cash equivalents 	1 700 	2 828
Discovery’s cash flows from operating activities decreased to R7 036 million (2025: R8 667 million) attributable to:
Cash generated from operations increased to R2 867 million (2025: R1 289 million) which was supported by
favourable underwriting experience across the insurance entities and positive contributions from Discovery Health
and Discovery Vitality.This was offset by higher taxation paid and a lower net inflow from operating assets and
liabilities of R6 790 million (2025: R9 167 million), mainly reflecting stronger growth in loans and advances relative to
deposits in Discovery Bank.
Net cash used in investing activities increased to R4 798 million (2025: R1 823 million), mainly due to the acquisition
of 1 Discovery Place, the Group’s South African head office, for R4.05 billion excluding VAT, which is reflected in
higher purchases of property and equipment. These outflows were partly offset by proceeds of R801 million from the
disposal of a portion of the Group’s stake in Cambridge Mobile Telematics and dividends received from equity-
accounted investments of R566 million.
Cash used in financing activities reduced to R538 million (2025: R4 016 million), mainly due to higher proceeds from
borrowings raised to fund the 1 Discovery Place acquisition. This was partly offset by higher repayments of
borrowings and lease liabilities and higher dividends paid to ordinary shareholders. The Group statement of cash
flows includes policyholder-related flows and those arising from the consolidated Discovery Unit Trusts. To assist in
understanding cash flows not distorted by these items, a Group shareholder free cash movement has been included
in the additional analyst information published on Discovery’s website.
B.4.2 	SHAREHOLDER CASH AND CASH EQUIVALENTS
R million 	Shareholder
Unit-linked
investment
and insurance
contracts1 	Total
Cash and cash equivalents at beginning of the year 	17 216 	4 750 	21 966
Effects of exchange rate changes on cash and cash equivalents 	(762) 	– 	(762)
Increase in cash and cash equivalents 	1 483 	217 	1 700
Cash and cash equivalents at end of the year 	17 937 	4 967 	22 904
1 Includes cash held within specific portfolios to match specific insurance liabilities.
Included in shareholder cash, is the cash held in the Group’s insurance entities which is used to fund new business
and match claims and other policyholder-related liabilities. This cash, together with the cash balances held by
Discovery Bank of R4.9 billion (30 June 2025: R6.3 billion), although unencumbered, is held for specific purposes and
therefore not considered available for distribution.
Cash available to support Group liquidity requirements is R3.9 billion (30 June 2025: R2.6 billion). In addition, the
Group also has undrawn revolving credit facilities of R2.6 billion at 30 June 2026.
B. 	Other significant items in these results continued
40
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
B.5 	Consolidation of Discovery Unit Trusts
Unit trusts that the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into
Discovery’s results for accounting purposes, which results in the recognition of the underlying assets and liabilities of
each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for
shareholders. Assets and liabilities of these Discovery Unit Trusts however increased by R5 214 million, compared to
the prior financial year ended 30 June 2025, with movements in the following line items on the Group’s statement of
financial position:
R million
Group
2026
Group
2025 	Movements
Investments at fair value through profit or loss 	38 211 	32 513 	5 698
Contract receivables and other receivables 	1 394 	1 214 	180
Cash and cash equivalents 	2 226 	2 910 	(684)
Other assets 	31 	11 	20
Total change in assets 	41 862 	36 648 	5 214
Third-party interest in consolidated funds 	40 901 	35 932 	4 969
Borrowings at amortised costs (bank overdraft) 	– 	2 	(2)
Other financial payables at amortised cost 	762 	626 	136
Liabilities arising from insurance contracts issued 	164 	73 	91
Other liabilities 	35 	15 	20
Total change in liabilities 	41 862 	36 648 	5 214
1 The comparatives have been restated, as communicated in the interim results for the six months ended 31 December 2025, to reflect the impact of
consolidating the global multi-asset investment funds managed through Discovery Mauritius Asset Management, in line with the presentation of the impact
in the current reporting period.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The net cash outflow of the
movement in policyholder investments for the period is R804 million (2025: R632 million) and has been included in
the 'Increase in operating assets’ line item on the Group’s statement of cash flows.
B.6 	Changes in Directorate
Changes to the Board of Discovery Limited from 1 July 2025 to the date of this announcement are as follows:
■ Ms VN Fakude has been appointed as an independent non-executive director with effect from 1 September 2025.
She is a member of the Discovery Limited Nominations, Remuneration and Social and Ethics Committees. Her
appointment will further augment the Board’s global business experience and expertise while improving its diversity.
B. 	Other significant items in these results continued
41	40

-- 22 of 49 --

B.7 	Events after reporting date
The following non-adjusting events occurred between the end of the reporting period and the date when the
financial statements were authorised for issue.
B.7.1 	DIVIDEND DECLARATION IN RESPECT OF THE YEAR ENDED 30 JUNE 2026
B PREFERENCE SHARE CASH DIVIDEND DECLARATION
On Thursday, 27 August 2026, the Board of Directors declared a final gross cash dividend of 510.47945 cents
(408.38356 cents net of dividend withholding tax) per B preference share for the period 1 January 2026 to
30 June 2026, payable from the income reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt. The issued preference
share capital at the declaration date is 8 million B preference shares. The salient dates for the dividend will be as
follows:
Last day of trade to receive a dividend 	Monday, 21 September 2026
Shares commence trading “ex” dividend 	Tuesday, 22 September 2026
Record date 	Friday, 25 September 2026
Payment date 	Monday, 28 September 2026
B preference share certificates may not be dematerialised or rematerialised between Tuesday, 22 September 2026
and Friday, 25 September 2026, both days inclusive.
ORDINARY SHARE CASH DIVIDEND DECLARATION
On Wednesday, 2 September 2026, the Board of Directors declared a final gross cash dividend of 273.00000 cents
(218.40000 cents net of dividend withholding tax) per ordinary share, out of the income reserves of the Company.
A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The number of ordinary shares in issue at the date of declaration is 682 491 619. The salient dates for the dividend
will be as follows:
Last day of trade to receive a dividend 	Tuesday, 13 October 2026
Shares commence trading “ex” dividend 	Wednesday, 14 October 2026
Record date 	Friday, 16 October 2026
Payment date 	Monday, 19 October 2026
Ordinary share certificates may not be dematerialised or rematerialised between Wednesday, 14 October 2026 and
Friday, 16 October 2026, both days inclusive.
B. 	Other significant items in these results continued
42
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
B.7 	Events after reporting date continued
B.7.2 	NEW ACQUISITION OF SUBSIDIARY, ICARIO
Subsequent to the reporting date, on 1 September 2026, Discovery Limited’s wholly owned subsidiary, Vitality Group
International Incorporated (VGI), acquired 100% of the shares and voting rights in Icario Holdco Incorporated (Icario).
Icario is a United States of America (US)-based healthcare services company that provides end-to-end member
engagement solutions, primarily to US government-sponsored health plans, including Medicaid, Medicare Advantage
and Dual Eligible Special Needs (D-SNP) plans. The acquisition enables VGI to accelerate its growth in the government-
sponsored health plan segment in the US, while strengthening its member activation, engagement and health plan
capabilities. The transaction enhances VGI’s scale, market position and access to a strategically important customer
segment and supports future growth through expanded product capabilities and cross-sell opportunities.
The acquisition is within the scope of IFRS 3 Business Combinations, which requires Discovery to apply the acquisition
method and determine the fair values of the identifiable assets acquired and liabilities assumed. As the acquisition
completed shortly before the financial statements were approved for issue, the purchase price allocation remains
provisional. The provisional assessment is subject to finalisation of the valuation of closing net assets and liabilities
assumed, customer relationships, contingent consideration and any resulting goodwill.
Total consideration transferred and liabilities assumed
Million 	Amounts in USD 	Amounts in ZAR	Million
Upfront cash consideration 	27 432 	435
Contingent consideration1 	Up to 32.5 	Up to 523
Total purchase consideration 	27 up to 59.5 	435 up to 958
1 The contingent consideration is dependent on both Icario maintaining specified revenue levels in the near-term relative to the agreed baseline, as well as
an earn-out which may become payable based on contracted annual recurring revenue growth in the near-term. The final amount will vary depending
on actual performance.
No revenue, profit or loss of Icario has been included in the consolidated income statement for the reporting period,
as the acquisition occurred after the reporting date.
Acquired assets and liabilities
At the date of approval of these financial statements, Discovery has commenced the purchase price allocation
following the recent completion of the acquisition. The transaction was concluded on a debt-free and cash-free basis,
with adequate working capital. As the valuation of the net assets acquired and liabilities assumed has not yet been
finalised, the disclosures for each major class have not been provided separately. Once the valuation has been
finalised, Discovery will allocate the total consideration transferred, as disclosed above, to identifiable intangible
assets, including software and customer relationships, and/or any resulting goodwill. In determining the fair value
of customer relationships, Discovery will apply a multi-period excess earnings model, consistent with previous
acquisitions, which considers the present value of the net cash flows expected to be generated by those customer
relationships, excluding cash flows related to contributory assets.
B. 	Other significant items in these results continued
43	42

-- 23 of 49 --

44
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
CInsurance and
reinsurance contracts
related disclosure
45 C.1.1 	Insurance and reinsurance
contracts disclosures and
reconciliations
49 C.1.2.1 Summary of insurance contracts
issued and reinsurance contracts
held
54 C.1.2.2 Movement in insurance contract
balances: GMM
60 C.1.2.3 Movement in insurance contract
balances: VFA
62 C.1.2.4 Movement in reinsurance contract
balances: GMM
66 C.1.2.5 Insurance revenue
68 C.1.2.6 Net investment result
72 C.1.2.7 Summary effect of initially
recognised contracted net
of reinsurance
C.1.1 Insurance and reinsurance contracts disclosures and reconciliations
The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance
contracts held on Discovery’s financial position, financial performance and cash flows.
INTRODUCTION
IFRS 17 requires that in determining the level at which an aggregated group of insurance contracts can provide useful
information to the user, Discovery considers:
■ The type of contract which would consider the nature of the product and the measurement model.
■ The geographical areas that may expose the entity to different sets of risks, even for similar products.
■ Reportable segments.
Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below.
C. 	Insurance and reinsurance contracts related
disclosure
45
SA Life (Risk) | GMM
(Life: Individual Life, Dollar LifePlan,
Health Protection Plans, Standalone Global Educator)
SA Invest (Risk) | GMM
(Guaranteed endowments)
SA Invest (Participating) | VFA
(Unit-linked invest products, Unit-linked insurance
products and Discovery Retirement Optimiser)
SA Life and Invest: Group Life and other | PAA
(Group Risk, Funeral and other including Discovery Card
Protector, Standalone Cancer Protector and LifeDrive)
SA Insure and other | PAA
(Personal lines, GAP and Trauma Cover, Travel Cover
and AfricaHealth)
UK Life (Risk) | GMM
(Own Licence and PAC book)
UK Health | PAA
(Private Medical Insurance)
44

-- 24 of 49 --

C.1.1 Insurance and reinsurance contracts disclosures and
reconciliations continued
The following index is a summary of all the quantitative disclosures set out in the notes:
Note 	Description
Analysis of
financial
position
C.1.2.1 Summary of insurance contracts
issued and reinsurance contracts held
Summary of movements
C.1.2.1.1 Contractual service margin and risk
adjustment1
C.1.2.1.2 Insurance finance reserve1
The note summarises the total value of insurance
and reinsurance contracts held as well as a
summary of movements in the CSM, risk adjustment
and IFR, across the disclosed portfolios. Insurance
and reinsurance contracts are presented separately
for portfolios in a net liability or net asset position.
Reconciliation of insurance contracts
Analysis by measurement component
GMM
C.1.2.2.1 SA Life (Risk)
C.1.2.2.2 SA Invest (Risk)
C.1.2.2.3 UK Life (Risk)
VFA
C.1.2.3.1 SA Invest (Participating)
Reconciliation of reinsurance contracts
Analysis by measurement component
GMM
C.1.2.4.1 SA Life (Risk)
C.1.2.4.2 UK Life (Risk)
The notes provide a detailed reconciliation of
disclosed portfolios showing the build-up of the
measurement components, namely:
■ Estimates of the present value of expected
fulfilment cash flows.
■ The Risk adjustment.
■ The Contractual service margin reflects unearned
profit. The CSM is further separated to reflect how
the CSM was calculated at transition, being
modified retrospectively or fully retrospectively.
C. 	Insurance and reinsurance contracts related
disclosure continued
46
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
C.1.1 Insurance and reinsurance contracts disclosures and
reconciliations continued
Note 	Description
Analysis of
income
statement
C.1.2.5 Insurance revenue 	The note provides a breakdown of the makeup of
insurance revenue for each disclosed portfolio
business unit.
For those contracts not measured using the PAA
approach, the amount reflects the provision of
services and the recovery of insurance acquisition
cash flows. The provision of services is represented
by the change in the LRC, namely:
■ CSM recognised during the period for the service
provided.
■ The change in the Risk adjustment for non-
financial risk.
■ Expected claims and insurance services expenses.
■ Experience adjustments.
C.1.2.6 Net investment result 	The note provides a holistic view of the following:
■ The investment returns on financial assets held.
■ The insurance and reinsurance finance income
and expenses, including the amounts recognised
in profit or loss and other comprehensive income
(OCI).
Additional
information
Effect of contracts initially recognised in
the period:
C.1.2.7 Effect of insurance contracts initially
recognised in the year.
C.1.2.7 Effect of reinsurance contracts initially
recognised in the year.
The notes provide a breakdown of the contracts
initially recognised during the period for each
disclosed portfolio business unit.
■ For insurance contracts, differentiate between
profitable contracts recognised with CSM and
onerous contracts.
■ Reinsurance contracts reflect contracts originated
with and without the loss-recovery component.
1 New notes summarising the movements in the CSM, Risk adjustment and IFR across the disclosed portfolios.
C. 	Insurance and reinsurance contracts related
disclosure continued
47	46

-- 25 of 49 --

C.1.1 Insurance and reinsurance contracts disclosures and
reconciliations continued
DEFINITIONS AND ABBREVIATIONS
The following abbreviations and terms are commonly used within the accounting policy:
Abbreviation or
definition 	Meaning
CSM 	Contractual Service Margin
DISCOVERY 	Discovery Group
DPF 	Direct Participation Features
DRO 	Discovery Retirement Optimiser
EFCF 	Expected Fulfilment Cash Flows
FINANCIAL RISK 	The risk of a possible future change in one or more of a specified interest rate, financial
instrument price, commodity price, currency exchange rate, index of prices or rates, credit
rating or credit index or other variable, provided in the case of a non-financial variable that
the variable is not specific to a party to the contract.
GMM 	General Measurement Model
IACF 	Insurance Acquisition Cash Flows
IFIE 	Insurance finance income and expense comprises the change in the carrying amount of
the group of insurance contracts arising from:
■ The effect of the time value of money and changes in the time value of money, and
■ The effect of financial risk and changes in financial risk
IFR 	Insurance Finance Reserve
IFRS Accounting
Standards IFRS® Accounting Standards
IFRS 17 	IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023)
IFRS 17 margins 	IFRS 17 margins refers to the contractual service margin plus the risk adjustment
ISE 	Insurance Service Expenses
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
OCI 	Other Comprehensive Income
PAA 	Premium Allocation Approach
VFA 	Variable Fee Approach
C. 	Insurance and reinsurance contracts related
disclosure continued
48
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
C.1.2 Insurance and reinsurance contract disclosures and reconciliations
C.1.2.1 SUMMARY OF INSURANCE CONTRACTS ISSUED AND REINSURANCE CONTRACTS
HELD
Group
R million
(Assets)/Liabilities 	Navigation
SA Life
Risk
(GMM)
SA Invest
Risk
(GMM)
UK Life
Risk
(GMM)
SA Invest
Participating
(VFA)
SA Life:
Group Life
and other
(PAA)
SA Insure
and other
(PAA)
UK
Health
(PAA) 	Total
Year ended 30 June 2026
Insurance Contracts 	A= D + E 	(37 694) 	24 112 (21 083) 	103 729 	7 483 	770 	(4 859) 	72 458
Reinsurance Contracts 	B = F 	439 	– 	10 243 	– 	(1 035) 	3 	(13) 	9 637
Total 	C = A +B 	(37 255) 	24 112 (10 840) 	103 729 	6 448 	773 	(4 872) 	82 095
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract balances 	(37 694) 	– (21 083) 	– 	– 	(25) 	821 	(57 981)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(20) 	(5 680) 	(5 700)
Total 	D 	(37 694) 	– (21 083) 	– 	– 	(45) 	(4 859) (63 681)
Liabilities arising from
insurance contracts
– Insurance contract balances 	– 	24 112 	– 	103 729 	7 483 	815 	– 136 139
Total 	E 	– 	24 112 	– 	103 729 	7 483 	815 	– 136 139
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	– 	(1 035) 	(1) 	(13) 	(1 049)
Reinsurance contract liabilities 	439 	– 	10 243 	– 	– 	4 	– 	10 686
Total 	F 	439 	– 	10 243 	– 	(1 035) 	3 	(13) 	9 637
Year ended 30 June 2025
Insurance contracts 	A= D + E 	(23 002) 	23 580 	(20 180) 	88 150 	6 414 	734 	(4 865) 	70 831
Reinsurance contracts 	B = F 	370 	– 	8 751 	– 	(865) 	(84) 	(13) 	8 159
Total 	C = A +B 	(22 632) 	23 580 	(11 429) 	88 150 	5 549 	650 	(4 878) 	78 990
Insurance contracts issued
Assets arising from
insurance contracts
– Insurance contract balances 	(23 002) 	– 	(20 180) 	– 	– 	– 	884 	(42 298)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	– 	(5 749) 	(5 749)
Total 	D 	(23 002) 	– 	(20 180) 	– 	– 	– 	(4 865) (48 047)
Liabilities arising from
insurance contracts
– Insurance contract balances 	– 	23 580 	– 	88 150 	6 414 	734 	– 118 878
Total 	E 	– 	23 580 	– 	88 150 	6 414 	734 	– 118 878
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	– 	(865) 	(84) 	(13) 	(962)
Reinsurance contract liabilities 	370 	– 	8 751 	– 	9 121
Total 	F 	370 	– 	8 751 	– 	(865) 	(84) 	(13) 	8 159
Cross reference to related notes
of insurance contracts issued
– Analysis by measurement
component 	C.1.2.2.1 	C.1.2.2.2 C.1.2.2.3 	C.1.2.3
Cross reference to related notes
of reinsurance contracts held
– Analysis by measurement
component 	C.1.2.4.1 	C.1.2.4.2
C. 	Insurance and reinsurance contracts related
disclosure continued
49	48

-- 26 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.1 SUMMARY OF INSURANCE CONTRACTS ISSUED AND REINSURANCE CONTRACTS
HELD continued
C.1.2.1.1 Contractual service margin (CSM) and risk adjustment (RA)
ANALYSIS OF CSM AND RISK ADJUSTMENT NET OF REINSURANCE
SA Composite 	SA Composite 	UK Composite 	Discovery Group
Group
R million (Assets)/Liabilities
SA Life Risk (GMM) 	SA Invest Risk (GMM)
SA Invest Participating
(VFA) 	Total SA Composite 	UK Life Risk (GMM) 	Total
CSM 	RA 	Total 	CSM 	RA 	Total 	CSM 	RA 	Total 	CSM 	RA 	Total 	CSM 	RA 	Total 	CSM 	RA 	Total
Year ended 30 June 2026
Balance at beginning of the period 	22 687 	7 686 	30 373 	820 	190 	1 010 	7 108 	843 	7 951 	30 615 	8 719 	39 334 	7 598 	2 041 	9 639 	38 213 	10 760 	48 973
Changes that relate to current services 	(1 681) 	(607) 	(2 288) 	(318) 	(42) 	(360) 	(1 344) 	(176) 	(1 520) 	(3 343) 	(825) 	(4 168) 	(740) 	(243) 	(983) 	(4 083) 	(1 068) 	(5 151)
CSM release and risk adjustment changes for services
provided 	(1 681) 	(607) 	(2 288) 	(318) 	(42) 	(360) 	(1 446) 	(176) 	(1 622) 	(3 445) 	(825) 	(4 270) 	(740) 	(243) 	(983) 	(4 185) 	(1 068) 	(5 253)
Experience adjustments 	– 	– 	– 	– 	– 	– 	102 	– 	102 	102 	– 	102 	– 	– 	– 	102 	– 	102
Changes that relate to future services 	421 	44 	465 	134 	(86) 	48 	2 765 	190 	2 955 	3 320 	148 	3 468 	991 	462 	1 453 	4 311 	610 	4 921
New Business (contracts initially recognised in the
period) 	1 565 	452 	2 017 	97 	7 	104 	597 	77 	674 	2 259 	536 	2 795 	1 121 	411 	1 532 	3 380 	947 	4 327
Changes in estimates that adjust CSM 	(1 144) 	(357) 	(1 501) 	37 	(43) 	(6) 	2 168 	111 	2 279 	1 061 	(289) 	772 	(130) 	33 	(97) 	931 	(256) 	675
Changes in estimates that result in onerous contracts 	– 	(51) 	(51) 	– 	(50) 	(50) 	– 	2 	2 	– 	(99) 	(99) 	– 	18 	18 	– 	(81) 	(81)
Changes that relate to past services 	– 	(10) 	(10) 	– 	– 	– 	– 	– 	– 	– 	(10) 	(10) 	– 	– 	– 	– 	(10) 	(10)
Adjustment to liability for incurred claims 	– 	(10) 	(10) 	– 	– 	– 	– 	– 	– 	– 	(10) 	(10) 	– 	– 	– 	– 	(10) 	(10)
Net finance expenses from insurance contracts
(interest accretion) 	2 248 	3 892 	6 140 	80 	65 	145 	– 	67 	67 	2 328 	4 024 	6 352 	131 	13 	144 	2 459 	4 037 	6 496
Effects of movement in exchange rates 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(831) 	(228) 	(1 059) 	(831) 	(228) 	(1 059)
Net changes 	988 	3 319 	4 307 	(104) 	(63) 	(167) 	1 421 	81 	1 502 	2 305 	3 337 	5 642 	(449) 	4 	(445) 	1 856 	3 341 	5 197
Balance at the end of the period 	23 675 	11 005 	34 680 	716 	127 	843 	8 529 	924 	9 453 	32 920 	12 056 	44 976 	7 149 	2 045 	9 194 	40 069 	14 101 	54 170
Year ended 30 June 2025
Balance at beginning of the period 	23 772 	7 108 	30 880 	941 	135 	1 076 	6 306 	773 	7 079 	31 019 	8 016 	39 035 	7 592 	1 768 	9 360 	38 611 	9 784 	48 395
Changes that relate to current services 	(1 537) 	(569) 	(2 106) 	(395) 	(38) 	(433) 	(1 290) 	(186) 	(1 476) 	(3 222) 	(793) 	(4 015) 	(696) 	(221) 	(917) 	(3 918) 	(1 014) 	(4 932)
CSM release and risk adjustment changes for services
provided 	(1 537) 	(569) 	(2 106) 	(395) 	(38) 	(433) 	(1 324) 	(186) 	(1 510) 	(3 256) 	(793) 	(4 049) 	(696) 	(221) 	(917) 	(3 952) 	(1 014) 	(4 966)
Experience adjustments 	– 	– 	– 	– 	– 	– 	34 	– 	34 	34 	– 	34 	– 	– 	– 	34 	– 	34
Changes that relate to future services 	(1 728) 	72 	(1 656) 	179 	65 	244 	2 092 	189 	2 281 	543 	326 	869 	181 	396 	577 	724 	722 	1 446
New Business (contracts initially recognised in the
period) 	1 114 	374 	1 488 	245 	25 	270 	732 	89 	821 	2 091 	488 	2 579 	346 	395 	741 	2 437 	883 	3 320
Changes in estimates that adjust CSM 	(2 842) 	(286) 	(3 128) 	(66) 	17 	(49) 	1 360 	99 	1 459 	(1 548) 	(170) 	(1 718) 	(165) 	(4) 	(169) 	(1 713) 	(174) 	(1 887)
Changes in estimates that result in onerous contracts 	– 	(16) 	(16) 	– 	23 	23 	– 	1 	1 	– 	8 	8 	– 	5 	5 	– 	13 	13
Changes that relate to past services 	– 	5 	5 	– 	– 	– 	– 	– 	– 	– 	5 	5 	– 	– 	– 	– 	5 	5
Adjustment to liability for incurred claims 	– 	5 	5 	– 	– 	– 	– 	– 	– 	– 	5 	5 	– 	– 	– 	– 	5 	5
Net finance expenses from insurance contracts
(interest accretion) 	2 180 	1 070 	3 250 	95 	28 	123 	– 	67 	67 	2 275 	1 165 	3 440 	118 	(5) 	113 	2 393 	1 160 	3 553
Effects of movement in exchange rates 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	403 	103 	506 	403 	103 	506
Net changes 	(1 085) 	578 	(507) 	(121) 	55 	(66) 	802 	70 	872 	(404) 	703 	299 	6 	273 	279 	(398) 	976 	578
Balance at the end of the period 	22 687 	7 686 	30 373 	820 	190 	1 010 	7 108 	843 	7 951 	30 615 	8 719 	39 334 	7 598 	2 041 	9 639 	38 213 	10 760 	48 973
C. 	Insurance and reinsurance contracts related
disclosure continued
50
51
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
50

-- 27 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.1 SUMMARY OF INSURANCE CONTRACTS ISSUED AND REINSURANCE CONTRACTS
HELD continued
C.1.2.1.2 Insurance finance reserve
The following table sets out the insurance finance reserve for the insurance contracts issued and reinsurance
contracts held, net of their related tax effects.
SA Composite
UK
Composite
Discovery
Group
Group
R million
Accumulated (income)/expense
SA
Life Risk
(GMM)
SA Life:
Group Life
and other
(PAA) 	Total
UK Life
Risk
(GMM) 	Total
Year ended 30 June 2026
Balance at beginning of the period 	5 938 	(262) 	5 676 	(2 748) 	2 928
Net finance (income)/expense for insurance
contracts
Amounts recognised in OCI 	(11 797) 	419 	(11 378) 	(776) 	(12 154)
Related tax effects 	3 185 	(113) 	3 072 	194 	3 266
Net finance income/(expense) for reinsurance
contracts
Amounts recognised in OCI 	683 	(51) 	632 	13 	645
Related tax effects 	(184) 	13 	(171) 	(3) 	(174)
Balance at the end of the period 	(2 175) 	6 	(2 169) 	(3 320) 	(5 489)
Year ended 30 June 2025
Balance at beginning of the period 	7 003 	(214) 	6 789 	(1 957) 	4 832
Net finance (income)/expense for insurance
contracts
Amounts recognised in OCI 	(1 684) 	(74) 	(1 758) 	(1 203) 	(2 961)
Related tax effects 	455 	20 	475 	300 	775
Net finance income/(expense) for reinsurance
contracts
Amounts recognised in OCI 	221 	8 	229 	153 	382
Related tax effects 	(57) 	(2) 	(59) 	(41) 	(100)
Balance at the end of the period 	5 938 	(262) 	5 676 	(2 748) 	2 928
C. 	Insurance and reinsurance contracts related
disclosure continued
52 	53
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
52

-- 28 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.2 MOVEMENT IN INSURANCE CONTRACT BALANCES: GMM
C.1.2.2.1 SA LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
2026 	2025
Group
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
R million
(Assets)/Liabilities 	Navigation
Other
contracts
Other
contracts
Opening assets arising from insurance
contracts issued 	(58 654) 	8 357 	27 295 	(23 002) 	(54 499) 	7 811 	28 842 	(17 846)
Net balance at beginning of the year 	A 	(58 654) 	8 357 	27 295 	(23 002) 	(54 499) 	7 811 	28 842 	(17 846)
Changes in the income statement and
OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(2 000) 	(2 000) 	– 	– 	(1 862) 	(1 862)
Change in Risk Adjustment for
non-financial risk that relates to expired risk 	– 	(678) 	– 	(678) 	– 	(642) 	– 	(642)
Experience adjustments 	(569) 	– 	– 	(569) 	(724) 	– 	– 	(724)
Changes that relate to future services
Contracts initially recognised in the period 	(2 168) 	475 	1 777 	84 	(1 647) 	395 	1 286 	34
Changes in estimates that adjust CSM 	1 858 	(376) 	(1 482) 	– 	4 046 	(362) 	(3 684) 	–
Changes in estimates that result in onerous
contract losses or reversal of losses 	684 	(60) 	– 	624 	202 	(14) 	– 	188
Servicing expenses and commission for
onerous contracts 	18 	– 	– 	18 	13 	– 	– 	13
Changes that relate to past services
Adjustment to liability for incurred claims 	– 	(16) 	– 	(16) 	– 	6 	– 	6
Insurance service result 	B 	(177) 	(655) 	(1 705) 	(2 537) 	1 890 	(617) 	(4 260) 	(2 987)
Net finance expenses from insurance
contracts 	C 	(21 774) 	4 012 	2 671 	(15 091) 	(8 647) 	1 163 	2 713 	(4 771)
Net changes to income statement and
OCI 	D = B + C 	(21 951) 	3 357 	966 	(17 628) 	(6 757) 	546 	(1 547) 	(7 758)
Cash flows 	E 	2 936 	– 	– 	2 936 	2 602 	– 	– 	2 602
Net balance at the end of the year 	F = A + D + E 	(77 669) 	11 714 	28 261 	(37 694) 	(58 654) 	8 357 	27 295 	(23 002)
Closing assets arising from insurance
contracts issued 	(77 669) 	11 714 	28 261 	(37 694) 	(58 654) 	8 357 	27 295 	(23 002)
Net balance at the end of the year 	(77 669) 	11 714 	28 261 	(37 694) 	(58 654) 	8 357 	27 295 	(23 002)
C. 	Insurance and reinsurance contracts related
disclosure continued
54 	55
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
54

-- 29 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.2 MOVEMENT IN INSURANCE CONTRACT BALANCES: GMM continued
C.1.2.2.2 SA INVEST (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
2026 	2025
Group
Estimates
of PVFCF
RA for non-
financial risk
CSM
Total
Estimates
of PVFCF
RA for non-
financial risk
CSM
Total
R million
(Assets)/Liabilities 	Navigation
Other
contracts
Other
contracts
Opening liabilities arising from insurance
contracts issued 	22 570 	190 	820 	23 580 	23 489 	135 	941 	24 565
Net balance at beginning of the year 	A 	22 570 	190 	820 	23 580 	23 489 	135 	941 	24 565
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(318) 	(318) 	– 	– 	(395) 	(395)
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	(42) 	– 	(42) 	– 	(38) 	– 	(38)
Experience adjustments 	27 	– 	– 	27 	32 	– 	– 	32
Changes that relate to future services
Contracts initially recognised in the period 	(99) 	7 	97 	5 	(266) 	25 	245 	4
Changes in estimates that adjust CSM 	6 	(43) 	37 	– 	49 	17 	(66) 	–
Changes in estimates that result in onerous
contract losses or reversal of losses 	(6) 	(50) 	– 	(56) 	(5) 	23 	– 	18
Insurance service result 	B 	(72) 	(128) 	(184) 	(384) 	(190) 	27 	(216) 	(379)
Net finance expenses from insurance contracts 	C 	3 375 	65 	80 	3 520 	2 805 	28 	95 	2 928
Net changes to income statement and OCI 	D = B + C 	3 303 	(63) 	(104) 	3 136 	2 615 	55 	(121) 	2 549
Cash flows 	E 	(2 604) 	– 	– 	(2 604) 	(3 534) 	– 	– 	(3 534)
Net balance at the end of the year 	F = A + D + E 	23 269 	127 	716 	24 112 	22 570 	190 	820 	23 580
Closing liabilities arising from insurance
contracts issued 	23 269 	127 	716 	24 112 	22 570 	190 	820 	23 580
Net balance at the end of the year 	23 269 	127 	716 	24 112 	22 570 	190 	820 	23 580
C. 	Insurance and reinsurance contracts related
disclosure continued
56 	57
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
56

-- 30 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.2 MOVEMENT IN INSURANCE CONTRACT BALANCES: GMM continued
C.1.2.2.3 UK LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
2026 	2025
Group
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
R million
(Assets)/Liabilities 	Navigation
Other
contracts
Other
contracts
Opening assets arising from
insurance contracts issued 	(38 091) 	2 562 	15 349 	(20 180) 	(30 819) 	2 239 	13 311 	(15 269)
Net balance at beginning of the
year 	A 	(38 091) 	2 562 	15 349 	(20 180) 	(30 819) 	2 239 	13 311 	(15 269)
Changes in the income statement
and OCI
Changes that relate to current
services
CSM recognised for services
provided 	– 	– 	(1 461) 	(1 461) 	– 	– 	(1 332) 	(1 332)
Change in Risk Adjustment for non-
financial risk that relates to expired risk 	– 	(254) 	– 	(254) 	– 	(246) 	– 	(246)
Experience adjustments 	(132) 	– 	– 	(132) 	362 	– 	– 	362
Changes that relate to future
services
Contracts initially recognised in the
period 	(2 932) 	510 	2 836 	414 	(2 192) 	471 	2 128 	407
Changes in estimates that adjust
CSM 	164 	43 	(207) 	– 	(164) 	(2) 	166 	–
Changes in estimates that result in
onerous contract losses or reversal
of losses 	465 	34 	– 	499 	345 	9 	– 	354
Insurance service result 	B 	(2 435) 	333 	1 168 	(934) 	(1 649) 	232 	962 	(455)
Net finance expenses from insurance
contracts 	C 	(1 792) 	11 	357 	(1 424) 	(2 178) 	(39) 	298 	(1 919)
Net changes to income statement
and OCI 	D = B + C 	(4 227) 	344 	1 525 	(2 358) 	(3 827) 	193 	1 260 	(2 374)
Cash flows 	E 	(844) 	– 	– 	(844) 	(1 553) 	– 	– 	(1 553)
Effect of movements in exchange
rates 	F 	4 299 	(289) 	(1 711) 	2 299 	(1 892) 	130 	778 	(984)
Net balance at the end of the year 	G = A + D + E + F 	(38 863) 	2 617 	15 163 	(21 083) 	(38 091) 	2 562 	15 349 	(20 180)
Closing assets arising from insurance
contracts issued 	(38 863) 	2 617 	15 163 	(21 083) 	(38 091) 	2 562 	15 349 	(20 180)
Net balance at the end of the year 	(38 863) 	2 617 	15 163 	(21 083) 	(38 091) 	2 562 	15 349 	(20 180)
C. 	Insurance and reinsurance contracts related
disclosure continued
58 	59
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
58

-- 31 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.3 MOVEMENT IN INSURANCE CONTRACT BALANCES: VFA
C.1.2.3.1 SA INVEST (PARTICIPATING)
ANALYSIS OF MEASUREMENT COMPONENT
2026 	2025
Group 	CSM 	CSM
R million
(Assets)/Liabilities 	Navigation
Estimates
of PVFCF
RA for
non-
financial
risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Estimates
of PVFCF
RA for
non-
financial
risk
Transition:
Modified
retrospective
Other
contracts 	Total
Opening liabilities arising from
insurance contracts issued 	80 199 	843 	5 377 	1 731 	88 150 	66 642 	773 	5 275 	1 031 	73 721
Net balance at beginning of the year 	A 	80 199 	843 	5 377 	1 731 	88 150 	66 642 	773 	5 275 	1 031 	73 721
Changes in the income statement and
OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(1 014) 	(432) 	(1 446) 	– 	– 	(1 058) 	(266) 	(1 324)
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	(176) 	– 	– 	(176) 	– 	(186) 	– 	– 	(186)
Experience adjustments 	(189) 	– 	90 	12 	(87) 	(96) 	– 	56 	(22) 	(62)
Changes that relate to future services
Contracts initially recognised in the
period 	(629) 	77 	– 	597 	45 	(764) 	89 	– 	732 	57
Changes in estimates that adjust CSM1 	(2 279) 	111 	1 510 	658 	– 	(1 459) 	99 	1 104 	256 	–
Changes in estimates that result in
onerous contract losses or reversal of
losses 	(27) 	2 	– 	– 	(25) 	6 	1 	– 	– 	7
Insurance service result 	B 	(3 124) 	14 	586 	835 	(1 689) 	(2 313) 	3 	102 	700 	(1 508)
Net finance expenses from insurance
contracts1 	C 	12 698 	67 	– 	– 	12 765 	12 957 	67 	– 	– 	13 024
Net changes to income statement
and OCI 	D = B + C 	9 574 	81 	586 	835 	11 076 	10 644 	70 	102 	700 	11 516
Cash flows 	E 	4 503 	– 	– 	– 	4 503 	2 913 	– 	– 	– 	2 913
Net balance at the end of the year 	F = A + D + E 	94 276 	924 	5 963 	2 566 	103 729 	80 199 	843 	5 377 	1 731 	88 150
Closing liabilities arising from insurance
contracts issued 	94 276 	924 	5 963 	2 566 	103 729 	80 199 	843 	5 377 	1 731 	88 150
Net balance at the end of the year 	94 276 	924 	5 963 	2 566 	103 729 	80 199 	843 	5 377 	1 731 	88 150
1 Effective 1 July 2025, the Group updated the presentation of IFIE for the VFA portfolios in line with evolving industry disclosure practices. IFIE, which was
previously presented separately, is now included within changes in estimates that adjust the CSM. The comparative information has been restated to align
with the current period presentation.
C. 	Insurance and reinsurance contracts related
disclosure continued
60 	61
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
60

-- 32 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.4 MOVEMENT IN REINSURANCE CONTRACT BALANCES: GMM
C.1.2.4.1 SA LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
2026 	2025
Group 	CSM 	CSM
R million
(Assets)/Liabilities 	Navigation
Estimates
of PVFCF
RA for
non-
financial
risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Estimates
of PVFCF
RA for non-
financial
risk
Transition:
Modified
retro-
spective
Other
contracts 	Total
Opening liabilities arising from
reinsurance contracts held 	5 649 	(671) 	(104) 	(4 504) 	370 	5 899 	(703) 	(100) 	(4 970) 	126
Net balance at beginning of the
year 	A 	5 649 	(671) 	(104) 	(4 504) 	370 	5 899 	(703) 	(100) 	(4 970) 	126
Changes in the income statement
and OCI
Changes that relate to current
services
CSM recognised for services
provided 	– 	– 	7 	312 	319 	– 	– 	6 	319 	325
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	71 	– 	– 	71 	– 	73 	– 	– 	73
Experience adjustments 	260 	– 	– 	– 	260 	624 	– 	– 	– 	624
Changes that relate to future
services
Contracts initially recognised in the
period 	220 	(23) 	– 	(212) 	(15) 	187 	(21) 	– 	(172) 	(6)
Changes in estimates that adjust
CSM 	(349) 	19 	– 	338 	8 	(897) 	76 	3 	839 	21
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts 	(63) 	9 	– 	– 	(54) 	(19) 	(2) 	– 	– 	(21)
Changes that relate to past
services
Adjustment to assets for incurred
claims 	– 	6 	– 	– 	6 	– 	(1) 	– 	– 	(1)
Net Expenses from reinsurance
contracts held 	B 	68 	82 	7 	438 	595 	(105) 	125 	9 	986 	1 015
Net finance income from
reinsurance contracts 	C 	1 342 	(120) 	(13) 	(410) 	799 	1 035 	(93) 	(13) 	(520) 	409
Net changes to income
statement and OCI 	D = B + C 	1 410 	(38) 	(6) 	28 	1 394 	930 	32 	(4) 	466 	1 424
Cash flows 	E 	(1 325) 	– 	– 	– 	(1 325) 	(1 180) 	– 	– 	– 	(1 180)
Net balance at the end of the year 	F = A + D + E 	5 734 	(709) 	(110) 	(4 476) 	439 	5 649 	(671) 	(104) 	(4 504) 	370
Closing liabilities arising from
reinsurance contracts held 	5 734 	(709) 	(110) 	(4 476) 	439 	5 649 	(671) 	(104) 	(4 504) 	370
Net balance at the end of the
year 	5 734 	(709) 	(110) 	(4 476) 	439 	5 649 	(671) 	(104) 	(4 504) 	370
C. 	Insurance and reinsurance contracts related
disclosure continued
62 	63
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
62

-- 33 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.4 MOVEMENT IN REINSURANCE CONTRACT BALANCES: GMM continued
C.1.2.4.2 UK LIFE (RISK)
ANALYSIS BY MEASUREMENT COMPONENT
2026 	2025
Group 	CSM 	CSM
R million
(Assets)/Liabilities 	Navigation
Estimates of
PVFCF
RA for non-
financial risk
Other
contracts 	Total
Estimates of
PVFCF
RA for non-
financial risk
Other
contracts 	Total
Opening liabilities arising from
reinsurance contracts held 	17 023 	(521) 	(7 751) 	8 751 	11 460 	(471) 	(5 719) 	5 270
Net balance at beginning of the
year 	A 	17 023 	(521) 	(7 751) 	8 751 	11 460 	(471) 	(5 719) 	5 270
Changes in the income
statement and OCI
Changes that relate to current
services
CSM recognised for services
provided 	– 	– 	721 	721 	– 	– 	636 	636
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	11 	– 	11 	– 	25 	– 	25
Experience adjustments 	186 	– 	– 	186 	(130) 	– 	– 	(130)
Changes that relate to future
services
Contracts initially recognised in
the period 	1 519 	(99) 	(1 715) 	(295) 	1 574 	(76) 	(1 782) 	(284)
Changes in estimates that adjust
CSM 	(67) 	(10) 	77 	– 	333 	(2) 	(331) 	–
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts 	(212) 	(16) 	– 	(228) 	(81) 	(4) 	– 	(85)
Net Expenses from reinsurance
contracts held 	B 	1 426 	(114) 	(917) 	395 	1 696 	(57) 	(1 477) 	162
Net finance income from
reinsurance contracts 	C 	642 	2 	(226) 	418 	598 	34 	(180) 	452
Net changes to income
statement and OCI 	D = B + C 	2 068 	(112) 	(1 143) 	813 	2 294 	(23) 	(1 657) 	614
Cash flows 	E 	1 725 	– 	– 	1 725 	2 460 	– 	– 	2 460
Effect of movements in exchange
rates 	F 	(1 987) 	61 	880 	(1 046) 	809 	(27) 	(375) 	407
Net balance at the end of the year G = A + D + E + F 	18 829 	(572) 	(8 014) 	10 243 	17 023 	(521) 	(7 751) 	8 751
Closing liabilities arising from
reinsurance contracts held 	18 829 	(572) 	(8 014) 	10 243 	17 023 	(521) 	(7 751) 	8 751
Net balance at the end of the
year 	18 829 	(572) 	(8 014) 	10 243 	17 023 	(521) 	(7 751) 	8 751
C. 	Insurance and reinsurance contracts related
disclosure continued
64 	65
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
64

-- 34 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.5 INSURANCE REVENUE
The following tables present an analysis of the insurance revenue recognised in the period.
Group
R million
Income/(expenses)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
UK Life Risk
(GMM)
SA Invest
Participating
(VFA)
SA Life:
Group life
and other
(PAA)
SA Insure
and other
(PAA)
UK Health
(PAA) 	Total
Year ended 30 June 2026
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	13 499 	996 	5 758 	2 849 	– 	– 	– 	23 102
– CSM recognised for services provided 	2 000 	318 	1 461 	1 446 	– 	– 	– 	5 225
– Change in risk adjustment for non-financial risk for risk expired 	675 	41 	246 	173 	– 	– 	– 	1 135
– Expected incurred claims and other insurance service expenses 	10 843 	627 	3 961 	1 147 	– 	– 	– 	16 578
– Experience adjustments 	(19) 	10 	90 	83 	– 	– 	– 	164
Recovery of insurance acquisition cash flows 	2 348 	173 	3 426 	778 	– 	– 	– 	6 725
Contracts not measured under the PAA 	15 847 	1 169 	9 184 	3 627 	– 	– 	– 	29 827
Contracts measured under the PAA 	– 	– 	– 	– 	3 762 	7 242 	20 611 	31 615
Total insurance revenue 	15 847 	1 169 	9 184 	3 627 	3 762 	7 242 	20 611 	61 442
Year ended 30 June 2025
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	13 257 	975 	5 014 	2 574 	– 	– 	– 	21 820
– CSM recognised for services provided 	1 862 	395 	1 332 	1 324 	– 	– 	– 	4 913
– Change in risk adjustment for non-financial risk for risk expired 	640 	36 	239 	167 	– 	– 	– 	1 082
– Expected incurred claims and other insurance service expenses 	10 712 	502 	3 565 	986 	– 	– 	– 	15 765
– Experience adjustments 	43 	42 	(122) 	97 	– 	– 	– 	60
Recovery of insurance acquisition cash flows 	2 162 	228 	3 036 	783 	– 	– 	– 	6 209
Contracts not measured under the PAA 	15 419 	1 203 	8 050 	3 357 	– 	– 	– 	28 029
Contracts measured under the PAA 	– 	– 	– 	– 	3 738 	6 822 	19 124 	29 684
Total insurance revenue 	15 419 	1 203 	8 050 	3 357 	3 738 	6 822 	19 124 	57 713
C. 	Insurance and reinsurance contracts related
disclosure continued
66 	67
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
66

-- 35 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.6 NET INVESTMENT RESULT
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million
Income/(expenses)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
UK Life Risk
(GMM)
SA Invest
Participating
(VFA)
SA Life:
Group Life
and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Health
(PAA)
Other
businesses 	Total
Year ended 30 June 2026
Investment return
Interest revenue from financial assets not measured at FVTPL 	48 	– 	74 	50 	– 	4 	180 	761 	1 117
Net gains on FVTPL investments 	9 	3 524 	– 	12 819 	477 	– 	42 	9 268 	26 139
Total investment return 	57 	3 524 	74 	12 869 	477 	4 	222 	10 029 	27 256
Movement in investment contract liabilities 	(3 894) 	(3 894)
Movement in third party interests in consolidated funds 	(4 317) 	(4 317)
Finance income/(expenses) from insurance contracts
Amounts recognised in profit or loss 	3 294 	(3 520) 	648 	(12 765) 	(469) 	(19) 	– 	– 	(12 831)
– Changes in fair value of underlying items of direct participation contracts 	– 	– 	– 	(12 765) 	– 	– 	– 	– 	(12 765)
– Interest accreted to the CSM 	(3 333) 	(80) 	(335) 	– 	– 	– 	– 	– 	(3 748)
– Interest on FCF and other finance (income)/expenses 	6 627 	(1 604) 	983 	– 	(469) 	(19) 	– 	– 	5 518
– Effect of changes in interest rates and other financial assumptions 	– 	(1 836) 	– 	– 	– 	– 	– 	– 	(1 836)
Amounts recognised in OCI 	11 797 	– 	776 	– 	(419) 	– 	– 	– 	12 154
– Interest accreted to the CSM 	575 	– 	(22) 	– 	– 	– 	– 	– 	553
– Interest on FCF and other finance (income)/expenses 	(2 631) 	– 	404 	– 	63 	– 	– 	– 	(2 164)
– Effect of changes in interest rates and other financial assumptions 	13 231 	– 	251 	– 	(495) 	– 	– 	– 	12 987
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	755 	– 	143 	– 	– 	– 	– 	– 	898
– Effect of movements in exchange rates 	(133) 	– 	– 	– 	13 	– 	– 	– 	(120)
Net finance expenses from insurance contracts 	15 091 	(3 520) 	1 424 	(12 765) 	(888) 	(19) 	– 	– 	(677)
Finance income/(expenses) from reinsurance contracts
Amounts recognised in profit or loss 	(116) 	– 	(405) 	– 	57 	– 	– 	– 	(464)
– Interest accreted to the CSM 	473 	– 	213 	– 	– 	– 	– 	– 	686
– Interest on FCF and other finance (income)/expenses 	(589) 	– 	(618) 	– 	57 	– 	– 	– 	(1 150)
Amounts recognised in OCI 	(683) 	– 	(13) 	– 	51 	– 	– 	– 	(645)
– Interest accreted to the CSM 	(39) 	– 	13 	– 	– 	– 	– 	– 	(26)
– Interest on FCF and other finance (income)/expenses 	184 	– 	(88) 	– 	(5) 	– 	– 	– 	91
– Effect of changes in interest rates and other financial assumptions 	(792) 	– 	213 	– 	69 	– 	– 	– 	(510)
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	(41) 	– 	(151) 	– 	– 	– 	– 	– 	(192)
– Effect of movements in exchange rates 	5 	– 	– 	– 	(13) 	– 	– 	– 	(8)
Net finance income from reinsurance contracts 	(799) 	– 	(418) 	– 	108 	– 	– 	– 	(1 109)
C. 	Insurance and reinsurance contracts related
disclosure continued
68 	69
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
68

-- 36 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.6 NET INVESTMENT RESULT continued
Group
R million
Income/(expenses)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
UK Life Risk
(GMM)
SA Invest
Participating
(VFA)
SA Life:
Group Life
and other
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Health
(PAA)
Other
businesses 	Total
Year ended 30 June 2025
Investment return
Interest revenue from financial assets not measured at FVTPL 	3 	– 	76 	– 	– 	5 	154 	760 	998
Net gains on FVTPL investments 	29 	2 986 	– 	13 130 	503 	– 	70 	9 100 	25 818
Total investment return 	32 	2 986 	76 	13 130 	503 	5 	224 	9 860 	26 816
Movement in investment contract liabilities 	(3 810) 	(3 810)
Movement in third party interests in consolidated funds 	(4 394) 	(4 394)
Finance income/(expenses) from insurance contracts
Amounts recognised in profit or loss 	3 087 	(2 928) 	716 	(13 024) 	(496) 	(20) 	– 	– 	(12 665)
– Changes in fair value of underlying items of direct participation contracts 	– 	– 	– 	(13 024) 	– 	– 	– 	– 	(13 024)
– Interest accreted to the CSM 1 	(3 475) 	(95) 	(258) 	– 	– 	– 	– 	– 	(3 828)
– Interest on FCF and other finance (income)/expenses1 	6 562 	(1 838) 	974 	– 	(496) 	(20) 	– 	– 	5 182
– Effect of changes in interest rates and other financial assumptions 	– 	(995) 	– 	– 	– 	– 	– 	– 	(995)
Amounts recognised in OCI 	1 684 	– 	1 203 	– 	74 	– 	– 	– 	2 961
– Interest accreted to the CSM 	731 	– 	(40) 	– 	– 	– 	– 	– 	691
– Interest on FCF and other finance (income)/expenses 	(2 465) 	– 	1 061 	– 	81 	– 	– 	– 	(1 323)
– Effect of changes in interest rates and other financial assumptions 	2 309 	– 	125 	– 	(10) 	– 	– 	– 	2 424
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	1 151 	– 	57 	– 	– 	– 	– 	– 	1 208
– Effect of movements in exchange rates 	(42) 	– 	– 	– 	3 	– 	– 	– 	(39)
Net finance expenses from insurance contracts 	4 771 	(2 928) 	1 919 	(13 024) 	(422) 	(20) 	– 	– 	(9 704)
Finance income/(expenses) from reinsurance contracts
Amounts recognised in profit or loss 	(188) 	– 	(299) 	– 	64 	– 	– 	– 	(423)
– Interest accreted to the CSM 	509 	– 	156 	– 	– 	– 	– 	– 	665
– Interest on FCF and other finance (income)/expenses 	(697) 	– 	(455) 	– 	64 	– 	– 	– 	(1 088)
Amounts recognised in OCI 	(221) 	– 	(153) 	– 	(8) 	– 	– 	– 	(382)
– Interest accreted to the CSM 	(44) 	– 	24 	– 	– 	– 	– 	– 	(20)
– Interest on FCF and other finance (income)/expenses 	291 	– 	(260) 	– 	(8) 	– 	– 	– 	23
– Effect of changes in interest rates and other financial assumptions 	(229) 	– 	12 	– 	3 	– 	– 	– 	(214)
– Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	(242) 	– 	71 	– 	– 	– 	– 	– 	(171)
– Effect of movements in exchange rates 	3 	– 	– 	– 	(3) 	– 	– 	– 	–
Net finance income from reinsurance contracts 	(409) 	– 	(452) 	– 	56 	– 	– 	– 	(805)
1. Effective 1 July 2025, the Group updated the presentation of IFIE for the VFA portfolios in line with evolving industry disclosure practices. IFIE, which was
previously presented separately, is now included within changes in estimates that adjust the CSM. The comparative information has been restated to align
with the current period presentation
C. 	Insurance and reinsurance contracts related
disclosure continued
70 	71
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
70

-- 37 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.7 SUMMARY EFFECT OF INITIALLY RECOGNISED CONTRACTED NET OF REINSURANCE
R million
Assets/(Liabilities)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
SA Invest
Participating
(VFA)
UK Life Risk
(GMM)
Year ended 30 June 2026
Present value of estimated net cash inflows 	1 948 	97 	629 	1 413
Risk adjustment for non-financial risk 	(452) 	(7) 	(77) 	(411)
CSM 	(1 565) 	(97) 	(597) 	(1 121)
Losses recognised on initial recognition 	(69) 	(7) 	(45) 	(119)
Year ended 30 June 2025
Present value of estimated net cash inflows 	1 460 	266 	764 	618
Risk adjustment for non-financial risk 	(374) 	(25) 	(89) 	(395)
CSM 	(1 114) 	(245) 	(732) 	(346)
Losses recognised on initial recognition 	(28) 	(4) 	(57) 	(123)
C.1.2.7.1 Effect of contracts initially recognised in the period
INSURANCE CONTRACTS
Group 	Profitable contracts issued 	Onerous contracts issued
Total
R million
Assets/(Liabilities)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
SA Invest
Participating
(VFA)
UK Life
Risk
(GMM)
SA Life Risk
(GMM)
SA Invest
Risk
(GMM)
SA Invest
Participating
(VFA)
UK Life
Risk
(GMM)
Year ended 30 June 2026
Insurance acquisition cash flows 	(1 552) 	(116) 	(670) 	(5 763) 	(177) 	(5) 	(116) 	(1 398) 	(9 797)
Claims and other insurance service expenses payable 	(2 745) 	(2 292) 	(10 246) 	(9 243) 	(370) 	(107) 	(1 863) 	(3 054) 	(29 920)
Estimates of present value of cash outflows 	(4 297) 	(2 408) 	(10 916) 	(15 006) 	(547) 	(112) 	(1 979) 	(4 452) 	(39 717)
Estimates of present value of cash inflows 	6 512 	2 510 	11 580 	18 271 	500 	109 	1 944 	4 119 	45 545
Risk adjustment for non-financial risk 	(438) 	(5) 	(67) 	(429) 	(37) 	(2) 	(10) 	(81) 	(1 069)
CSM 	(1 777) 	(97) 	(597) 	(2 836) 	– 	– 	– 	– 	(5 307)
Losses recognised on initial recognition 	– 	– 	– 	– 	(84) 	(5) 	(45) 	(414) 	(548)
Year ended 30 June 2025
Insurance acquisition cash flows 	(1 465) 	(160) 	(567) 	(4 956) 	(112) 	(11) 	(87) 	(1 276) 	(8 634)
Claims and other insurance service expenses payable 	(2 050) 	(3 640) 	(9 543) 	(7 284) 	(180) 	(215) 	(840) 	(2 918) 	(26 670)
Estimates of present value of cash outflows 	(3 515) 	(3 800) 	(10 110) 	(12 240) 	(292) 	(226) 	(927) 	(4 194) 	(35 304)
Estimates of present value of cash inflows 	5 176 	4 063 	10 913 	14 760 	278 	229 	888 	3 866 	40 173
Risk adjustment for non-financial risk 	(375) 	(18) 	(71) 	(392) 	(20) 	(7) 	(18) 	(79) 	(980)
CSM 	(1 286) 	(245) 	(732) 	(2 128) 	– 	– 	– 	– 	(4 391)
Losses recognised on initial recognition 	– 	– 	– 	– 	(34) 	(4) 	(57) 	(407) 	(502)
C. 	Insurance and reinsurance contracts related
disclosure continued
72 	73
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
72

-- 38 of 49 --

C.1.2 Insurance and reinsurance contract disclosures and reconciliations
continued
C.1.2.7 SUMMARY EFFECT OF INITIALLY RECOGNISED CONTRACTED NET OF
REINSURANCE continued
C.1.2.7.1 Effect of contracts initially recognised in the period continued
REINSURANCE CONTRACTS
Group
Group of contracts with a
net cost on initial
recognition1
Total
R million
(Assets)/Liabilities
SA Life Risk
(GMM)
UK Life Risk
(GMM)
Year ended 30 June 2026
Estimates of present value of cash outflows 	(1 254) 	(15 490) 	(16 744)
Estimates of present value of cash inflows 	1 034 	13 971 	15 005
Risk adjustment for non-financial risk 	23 	99 	122
Income recognised on initial recognition (for offset) 	(15) 	(295) 	(310)
CSM 	(212) 	(1 715) 	(1 927)
Year ended 30 June 2025
Estimates of present value of cash outflows 	(1 032) 	(13 919) 	(14 951)
Estimates of present value of cash inflows 	845 	12 345 	13 190
Risk adjustment for non-financial risk 	21 	76 	97
Income recognised on initial recognition (for offset) 	(6) 	(284) 	(290)
CSM 	(172) 	(1 782) 	(1 954)
1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect as a future
cost relative to the insurance contract CSM that will release as future revenue.
C. 	Insurance and reinsurance contracts related
disclosure continued
74
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
75
DAccounting policies
76 D.1 	New Accounting Standards and
amendments to published
Accounting Standards not yet
effective
77 D.2 	Normalised headline earnings
77 D.3 	Basis of preparation
74

-- 39 of 49 --

D.1 	New Accounting Standards and amendments to published
Accounting Standards not yet effective
The Group has not early adopted any other IFRS Accounting Standards, amendments or interpretations that have
been issued but not yet effective. The Group does not expect any new IFRS Accounting Standards, amendments or
interpretations that have been issued but not yet effective to have a material impact on the recognised amounts
except for IFRS 18 Presentation and disclosure in Financial Statements (IFRS 18), which supersedes IAS 1 Presentation of
Financial Statements (IAS 1) and provides additional requirements for the presentation and disclosure of information
in the primary financial statements and the notes to improve transparency and comparability of information. For the
Group, IFRS 18 will be effective from 1 July 2027. The Group is assessing additional disclosure requirements required.
For the financial year commencing 1 July 2025, there were no material new standards, amendments or
interpretations that became effective for the Group.
INTEREST RATE BENCHMARK REFORMS (IBOR)
In recent years, major interest rate benchmarks have been reformed globally, resulting in the replacement of certain
interbank offered rates (IBORs) with alternative reference rates. Discovery Limited has financial instruments that
have been, or will be, affected by these market-wide reforms, most notably the transition from LIBOR to the Sterling
Overnight Index Average (SONIA) in the United Kingdom and the replacement of the Johannesburg Interbank Average
Rate (JIBAR) in South Africa.
The South African Reserve Bank (SARB) has confirmed that JIBAR will be permanently discontinued following its final
publication on 31 December 2026. Following an observation period from 1 November 2022 to 31 October 2023, the
South African Rand Overnight Index Average (ZARONIA) was endorsed as the successor benchmark rate. Industry
milestones leading up to the cessation of JIBAR included the transition to a ZARONIA-first approach for derivatives in
November 2024, the cash market in June 2025, and the cessation of new JIBAR-linked instruments from March 2026.
As at 30 June 2026, the Group’s JIBAR-linked exposure comprises:
■ SA Bank borrowings, with associated interest rate derivatives, as detailed in Note A.5.1
■ Investments of c. R10.4 billion
■ Home loans provided to customers of c. R3.9 billion
Certain secured floating-rate financial instruments within Discovery Bank are expected to transition directly from
JIBAR to the South African prime lending rate as the designated replacement benchmark. The Bank intends to rely on
the proposed amendments to the Financial Sector Regulation Act, expected to become effective towards the end of
2026, to facilitate the transition of these instruments.
The Group does not expect the benchmark reform to result in material accounting consequences. In accordance with
the IFRS Accounting Standards reliefs applicable to IBOR reform, changes to the contractual cash flows of financial
assets and liabilities arising directly from the reform will be accounted for as changes to the basis for determining
contractual cash flows. Accordingly, the effective interest rate will be updated to reflect the replacement benchmark
without recognising a gain or loss, provided that the new basis is economically equivalent to the previous basis.
For hedge accounting purposes, where cash flow hedges are affected by the reform, the Group will continue to apply
the available reliefs. When assessing whether a forecast transaction remains highly probable, the interest rate
benchmark on which the hedged cash flows are based is assumed to remain unchanged as a consequence of the
reform.
The transition is not expected to result in any changes to the Group’s or the Bank’s risk management strategies.
Management continues to monitor developments relating to benchmark reform, the transition of affected financial
instruments and the associated risk management implications.
D. 	Accounting policies
76
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
D.2 	Normalised headline earnings
The Group assesses its performance using normalised headline earnings, an alternative profit measure not under the
IFRS Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that
Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the
comparability and understanding of the financial performance of the Group.
Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be
comparable with similarly labelled measures and disclosures provided by other entities.
The Group calculates headline earnings in accordance with the latest SAICA circular: ’Headline Earnings’. NHEPS is
calculated by starting with headline earnings and adjusted to exclude material items that are not considered to be
part of the Group's normal operations as follows:
■ Once-off transactions – eg, restructuring costs, transaction costs related to interest rate derivatives and initial
deferred tax assets raised on previously unrecognised assessed losses
■ Unusual items – the Group considers items to be unusual when they have limited predictive value, or it is
reasonable that items of a similar nature would not necessarily arise for several future reporting periods
■ Income or expenses not considered to be part of the Group’s normal operations – for example, amortisation of
intangibles from business combinations and fair value gains or losses on foreign exchange contracts not
designated as hedges.
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in
accordance with the policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for
transparency and consistency.
D.3 	Basis of preparation
STATEMENT OF COMPLIANCE
Discovery Limited is a company incorporated in South Africa.
The condensed consolidated annual financial statements for the year ended 30 June 2026 (annual results)
consolidate the results of Discovery and its subsidiaries (together the Group) and equity account the Group’s
interests in associates and joint ventures.
The annual results comprise the Group statement of financial position at 30 June 2026, Group income statement,
Group statement of other comprehensive income, Group statement of changes in equity and Group statement of
cash flows for the year ended 30 June 2026 and selected explanatory notes.
The condensed consolidated annual financial statements have been prepared in accordance with the JSE Limited (JSE)
Listings Requirements, IFRS® Accounting Standards as issued by the International Accounting Standards Board (IFRS
Accounting Standards), including IAS 34 Interim Financial Reporting (IAS 34), the South African Institute of Chartered
Accountants (SAICA) Financial Reporting Guides as issued by the Accounting Practices Committee, the Financial
Pronouncements as issued by the Financial Reporting Standards Council (FRSC) and the requirements of the
Companies Act of South Africa.
The accounting policies adopted are consistent with the accounting policies applied in the prior annual financial
statements.
The financial information in these annual results has been extracted from the Group audited consolidated financial
statements for the year ended 30 June 2026, but is not itself audited. As such, these annual results do not include all
the notes typically included in the annual financial statements and must be read together with the Group audited
consolidated financial statements for the year ended 30 June 2026. The Board of Discovery takes full responsibility
for the accuracy of the extracted information.
The Group audited consolidated financial statements for the year ended 30 June 2026 were audited by KPMG Inc.
and Deloitte & Touche, who expressed an unmodified audit opinion. A copy of the set of Group audited consolidated
financial statements with the signatures of the directors is available at the Company’s registered office through a
secure electronic manner, at the election of the person requesting inspection.
D. 	Accounting policies continued
77	76

-- 40 of 49 --

78
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Embedded value
statement
79 Table 1: Group embedded value
80 Table 2: Value of in-force covered
business
81 Table 3: Group embedded value earnings
81 Table 4: Components of Group embedded
value earnings
82 Table 5: Experience variances
83 Table 6: Methodology and assumptions
changes
84 Table 7: Value of new business
86 Table 8: Embedded value economic
assumptions
88 Table 9: Embedded value sensitivity
88 Table 10: Value of new business
sensitivity
The embedded value of the Discovery Group consists of the following components:
■ the adjusted net worth attributed to the business at the valuation date;
■ plus: the present value of expected future shareholder cash flows from the in-force covered business;
■ less: the cost of required capital.
The present value of expected future shareholder cash flows from the in-force covered business is calculated as the value
of projected future after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk
discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business
liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital
requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows
of the new business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving
strain, initial expenses and cost of required capital. The value of new business is calculated using the current reporting date
assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group.
Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery
Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality
Group, Ping An Health Insurance, Discovery Insure, Discovery Bank and Umbrella Funds, no published value has been placed
on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-
convertible preference shares. For embedded value purposes this capital, net of share issue expenses, has been excluded
from the adjusted net worth.
Table 1: Group embedded value
R millions 	30 June 2026 	30 June 2025 	% Change
Shareholders’ funds 	82 661 	65 699 	26
Adjustment to shareholders’ funds from published basis1 	(52 264) 	(40 660) 	29
Adjusted net worth2 	30 397 	25 039 	21
Value of in-force covered business before cost of required capital 	116 089 	104 812 	11
Cost of required capital 	(3 562) 	(3 297) 	8
Discovery Group embedded value 	142 924 	126 554 	13
Number of shares (millions) 	672.6 	666.6
Embedded value per share 	R212.49 	R189.85 	12
Diluted number of shares (millions) 	675.0 	668.7
Diluted embedded value per share3 	R211.75 	R189.25 	12
1 A breakdown of the "Adjustment to shareholders’ funds from published basis" is shown in the table below. Note that where relevant, adjustments have been converted
using the closing exchange rate of R21.73/GBP (June 2025: R24.34/GBP).
R millions 	30 June 2026 	30 June 2025
Life net assets under insurance contracts 	(31 944) 	(21 333)
Vitality Life Limited net assets under insurance contracts 	(11 691) 	(11 663)
VitalityHealth Insurance Acquisition Cash Flow (IACF) Asset 	(5 049) 	(5 120)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(4) 	(7)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 689) 	(3 012)
Intangible assets (net of deferred tax) in covered businesses 	(556) 	(813)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting* 	– 	1 550
Equity settled share based payment mark-to-market adjustment** 	448 	517
Total 	(52 264) 	(40 660)
* The "Reversal of 1 Discovery Place IFRS 16 financial lease accounting" adjustment has reduced from R1.55 billion at 30 June 2025 to nil at 30 June 2026 following the
purchase of the 1 Discovery Place building. The historical EV adjustment is no longer required and has been replaced by a once-off gain of R1.07 billion (net of tax)
recognised on the termination of the lease arrangement, which is reflected in the Shareholders' funds and therefore forms part of the Adjusted net worth.
** The “Equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-market value of
the equity settled share based payments.
Embedded value statement
for the year ended 30 June 2026
79	78

-- 41 of 49 --

Table 1: Group embedded value continued
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value.
R millions 	30 June 2026 	30 June 2025
Shareholders’ funds 	82 661 	65 699
Adjustment to shareholders' funds 	(52 264) 	(40 660)
Adjusted net worth 	30 397 	25 039
Excess of available capital over adjusted net worth 	57 553 	52 419
Available capital 	87 950 	77 458
Required capital 	56 852 	48 446
Excess available capital 	31 098 	29 012
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available capital on a
regulatory solvency basis for covered business. This includes:
■ The net preference share capital of R779 million which is included as available capital.
■ The difference between Vitality Life Limited’s Solvency UK Pillar 1 Own Funds and its adjusted net worth.
■ The difference between Life’s SAM Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R millions 	30 June 2026 	30 June 2025
Health and Vitality 	1 328 	1 286
Life and Invest 	37 439 	29 349
VitalityHealth 	4 269 	4 761
VitalityLife 	13 816 	13 050
Total Required Capital 	56 852 	48 446
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, the required capital was set equal to 1.55 times the Solvency UK Pillar 1 Solvency Capital Requirement.
– For VitalityLife, the required capital was set equal to 1.4 times the Solvency UK Pillar 1 Solvency Capital Requirement.
The cost of required capital in the embedded value is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required
capital amount and, where relevant, an internally defined liquidity target capital requirement of tangible assets. As a result, changes in the required capital noted in the table
above may differ from changes in the cost of required capital, where the liquidity target capital requirement of tangible assets is the prevailing constraint. Additional detail is
provided in the ‘basis of preparation’ section.
3 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the impact is dilutive.
This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements.
Table 2: Value of in-force covered business
R millions
Value before
cost of
capital
Cost of
capital
Value after
cost of
capital
At 30 June 2026
Health and Vitality 	31 570 	(554) 	31 016
Life and Invest1 	52 233 	(1 771) 	50 462
VitalityHealth2 	17 041 	(461) 	16 580
VitalityLife2 	15 245 	(776) 	14 469
Total 	116 089 	(3 562) 	112 527
At 30 June 2025
Health and Vitality 	27 972 	(525) 	27 447
Life and Invest1 	42 869 	(1 614) 	41 255
VitalityHealth2 	18 395 	(526) 	17 869
VitalityLife2 	15 576 	(632) 	14 944
Total 	104 812 	(3 297) 	101 515
1 Included in the Life and Invest value of in-force covered business is R3 418 million (June 2025: R2 894 million) in respect of investment management services provided on
off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R21.73/GBP (June 2025: R24.34/GBP).
Embedded value statement continued
for the year ended 30 June 2026
80
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Table 3: Group embedded value earnings Year ended
R millions 	30 June 2026 	30 June 2025
Embedded value at end of period 	142 924 	126 554
Less: embedded value at beginning of period 	(126 554) 	(110 354)
Increase in embedded value 	16 370 	16 200
Dividends paid 	2 205 	1 707
Employee share option schemes 	(824) 	(721)
Net change in capital 	145 	23
Transfer to hedging reserve 	(52) 	104
Acquisition of subsidiaries with non-controlling interest 	1 	(1)
Embedded value earnings 	17 845 	17 312
Annualised return on opening embedded value 	14.1% 	15.7%
Table 4: Components of Group embedded value earnings
Year ended 30 June 2026
Year ended
30 June 2025
R millions 	Net Worth
Cost of
required
capital
Value of
inforce
covered
business
Embedded
Value
Embedded
Value
Total profit from new business (at point of sale) 	(7 234) 	(356) 	10 411 	2 821 	2 154
Profit from existing business
– Expected return 	9 777 	(5) 	1 175 	10 947 	10 878
– Change in methodology and assumptions1 	3 223 	(116) 	2 223 	5 330 	(404)
– Experience variances 	1 840 	78 	1 198 	3 116 	2 905
Impairment, amortisation and fair value
adjustment2 	(41) 	– 	– 	(41) 	(62)
Increase in goodwill and intangibles 	(344) 	– 	– 	(344) 	(382)
Non-covered businesses3 	2 819 	– 	– 	2 819 	2 537
Non-recurring expenses 	(280) 	– 	– 	(280) 	(355)
Acquisition costs4 	(64) 	– 	3 	(61) 	(45)
Finance costs5 	(3 018) 	– 	– 	(3 018) 	(3 125)
Foreign exchange rate movements6 	(1 204) 	133 	(3 732) 	(4 803) 	1 550
Other7 	(74) 	– 	– 	(74) 	(8)
Return on shareholders' funds5,8 	1 433 	– 	– 	1 433 	1 669
Embedded value earnings 	6 833 	(266) 	11 278 	17 845 	17 312
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the operating and
economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure in Vitality
Global.
3 This item includes the profits of non-covered businesses. Head office costs which relate to non-covered business are included in this item, as well as cR196 million of
expenses which are currently incurred by the covered businesses but will be met by non-covered businesses in due course, and hence have not been included in the
relevant covered businesses’ embedded value expense analysis. In addition, included in non-covered businesses is a net negative impact of R482 million relating to the
termination of the 1 Discovery Place lease, reflecting the reversal of the historical EV shareholder adjustment partly offset by a once-off termination gain (net of tax).
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been written over the
period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of new business and therefore the
costs are not deducted from the value of new business.
5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R1 367 million at 30 June 2026 and R1 351 million at 30 June 2025).
6 This item includes foreign exchange gains / (losses) emerging through the income statement, in addition to translation impacts on the cost of required capital and value of
in-force.
7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
8 The return on shareholders’ funds is shown net of tax and management charges.
Embedded value statement continued
for the year ended 30 June 2026
81	80

-- 42 of 49 --

Table 5: Experience variances
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Year
ended
30 June
2026
Year
ended
30 June
2025
R millions
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value
of
inforce 	Total 	Total
Renewal expenses 	37 	– 	(27) 	5 	(76) 	– 	(22) 	– 	(83) 	25
Lapses and surrenders1 	25 	339 	32 	129 	– 	(234) 	(93) 	125 	323 	1 583
Mortality and morbidity2 	– 	– 	1 105 	(105) 	530 	– 	151 	– 	1 681 	(462)
Policy alterations3 	– 	5 	(613) 	57 	– 	– 	8 	(70) 	(613) 	(761)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and Fee
Income 	197 	– 	10 	(84) 	(91) 	– 	4 	30 	66 	1 100
Inflation-linked
indexation 	– 	– 	3 	24 	– 	– 	6 	5 	38 	(130)
Economic 4 	– 	– 	157 	219 	180 	– 	– 	– 	556 	719
Tax 5 	168 	– 	(59) 	123 	(18) 	– 	242 	(2) 	454 	483
Reinsurance6 	– 	– 	– 	– 	– 	– 	(227) 	9 	(218) 	(94)
Maintain modelling
term7 	– 	357 	– 	108 	– 	229 	– 	– 	694 	566
Vitality benefits8 	88 	– 	– 	– 	– 	– 	4 	– 	92 	(116)
Other9 	– 	– 	131 	7 	– 	– 	(12) 	– 	126 	(8)
Total 	515 	701 	739 	483 	525 	(5) 	61 	97 	3 116 	2 905
1 For VitalityHealth, the lapse and surrender experience reflects lower than expected retained renewal premium increases, as a result of the business reducing renewal price
increases earlier than planned to support retention, given strong profit margin emergence. For Health and Vitality, the lapse and surrender experience reflects the success
of targeted interventions against the one-year stressed lapse assumption introduced in the prior period.
2 For Life and Invest, overall claims experience for the period was better than expected for Individual Life, Group Life and Invest lines of business. For VitalityHealth, this item
largely reflects the net impact of lower than expected claims.
3 For Life and Invest, and VitalityLife, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by
positive experience on lapses and premium income. A number of targeted interventions and management actions are currently being implemented, which are expected to
improve the observed experience in the short-term.
4 For Life and Invest, better than expected unit fund growth in Invest resulted in an improved projected fee income reflected in the value of in-force. In addition, this item includes
impacts arising from the IAS 12 deferred tax liability, driven by market movements. For VitalityHealth, investment return continued to contribute to profitability as interest
rates in the UK remain high.
5 The tax variance arises due to the difference in timing between expected and actual tax payments, as well as differences in the modelling of certain components of
expected taxable profit compared to actual taxable profit.
6 For VitalityLife, higher financial reinsurance repayments made over the period results in a lower outstanding deficit account balance, which is reflected as a positive
variance in the value of in-force and a negative variance in the net worth. In addition, for VitalityLife, higher than expected risk reinsurance premiums contributed to the
negative variance in net worth.
7 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each reporting period. Therefore, an experience variance arises because the
total term of the in-force covered business is effectively increased by twelve months.
8 For Health and Vitality, the experience is driven by successful benefit management initiatives in the Vitality business.
9 For Life and Invest, this relates to offsetting differences between the actual timing of cash flows and model expectation.
Embedded value statement continued
for the year ended 30 June 2026
82
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Table 6: Methodology and assumption changes
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Year
ended
30 June
2026
Year
ended
30 June
2025
R millions
Net
Worth
Value of
In-Force
Net
Worth
Value of
In-Force
Net
Worth
Value of
In-Force
Net
Worth
Value of
In-Force 	Total 	Total
Modelling changes1 	– 	(10) 	92 	(163) 	– 	– 	267 	(95) 	91 	(99)
Expenses2 	– 	(134) 	(32) 	(458) 	– 	– 	(37) 	(132) 	(793) 	(377)
Lapses3 	– 	(8) 	– 	(146) 	– 	– 	(147) 	25 	(276) 	(1 297)
Mortality and
morbidity4 	– 	– 	(206) 	345 	– 	– 	(52) 	(127) 	(40) 	1 034
Benefit changes5 	– 	(73) 	– 	– 	– 	– 	– 	– 	(73) 	17
Vitality6 	– 	– 	– 	– 	– 	– 	14 	158 	172 	–
Tax7 	– 	– 	– 	(334) 	– 	– 	– 	– 	(334) 	–
Economic assumptions8 	– 	493 	289 	5 194 	– 	(489) 	22 	242 	5 751 	174
Premium and fee
income9 	– 	401 	– 	– 	– 	– 	– 	– 	401 	196
Reinsurance and
financing10 	– 	– 	533 	(29) 	– 	– 	2 428 	(2 602) 	330 	104
Other 	– 	– 	39 	38 	– 	– 	13 	11 	101 	(156)
Total 	– 	669 	715 	4 447 	– 	(489) 	2 508 	(2 520) 	5 330 	(404)
1 Refinements to the modelling environment were introduced. For Life and Invest, this largely relates to updates for commission modelling, and for VitalityLife this reflects
modelling updates in respect of reinsurance retention.
2 For Health and Vitality, Life and Invest, and VitalityLife, the expense assumptions were updated to align to budget. For VitalityLife, expense assumptions were also updated
to align more closely at a benefit level. For Group Life, a comprehensive review of expenses resulted in a higher allocation to renewal expenses.
3 For Health and Vitality, the one-year stressed lapse assumption which was introduced in the prior period was retained for Vitality only, to allow time for specific
interventions to take effect. For Life and Invest, the lapse basis was updated to include the introduction of a one-year stressed assumption in respect of the phasing in of
management actions to address policy alterations experience. For VitalityLife, the item includes a strengthening of the VitalityLife Whole of Life lapse basis.
4 For Life and Invest, refinements to the mortality and morbidity assumptions on the Individual Life, Invest and Group Life businesses were implemented, which largely offset
in aggregate, with the net positive impact relating to aligning Group Life's claims assumption more closely to recent experience. For VitalityLife, the item reflects the impact
of updating mortality improvement assumptions.
5 For Health and Vitality, the Vitality profit margin assumption was updated to align to budget.
6 For VitalityLife, the Vitality status distribution and physical activity assumptions were updated to align with recent experience.
7 For Life and Invest, the Invest transfer tax modelling under IFRS17 for Embedded Value purposes was refined.
8 For Health and Vitality, and Life and Invest, the item includes the impact of updating the internally derived yield curves as at 30 June 2026. For Health and Vitality, this also
includes the impact of higher-than-expected inflation applicable to the administration and managed care fee escalation in 2026. For VitalityHealth, this includes the
impact of the increase in the risk discount rate, following the increase in the underlying risk-free rate, which results in a decrease in the Annuity Factor. For VitalityLife, this
item includes the impact of updating to the 30 June 2026 Solvency UK yield curves and IFRS interest rates.
9 For Health and Vitality, this item represents an additional administration and managed care fee margin effective for 2026. This additional margin is contractually effective
given a defined level of spend to enhance the services rendered by the administrator.
10 For Life and Invest, the reinsurance and financing item includes reinsurance optimisation initiatives and the impact of internal financing arrangements, where the future
expected cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities. For VitalityLife, this item includes the impact of
external financing arrangements, where future expected cash flows arising from part of the negative reserves are monetised to partially fund new business.
Embedded value statement continued
for the year ended 30 June 2026
83	82

-- 43 of 49 --

Table 7: Value of new business Year ended
R millions
30 June
2026
30 June
2025 	% Change
Health and Vitality
Gross profit from new business (at point of sale) 	1 506 	1 095
Cost of required capital 	(51) 	(45)
Present value of future profits from new business (at point of sale) after cost
of required capital 	1 455 	1 050 	39
New business annualised premium equivalent1 	6 919 	6 093 	14
Life and Invest
Present value of future profits from new business (at point of sale)2 	555 	535
Cost of required capital 	(86) 	(74)
Present value of future profits from new business (at point of sale) after cost
of required capital 	469 	461 	2
New business annualised premium equivalent3 	3 704 	3 270 	13
Annualised profit margin4 	1.6% 	1.8%
Annualised profit margin excluding Invest business 	3.8% 	2.1%
VitalityHealth5
Present value of future profits from new business (at point of sale) 	554 	671
Cost of required capital 	(60) 	(62)
Present value of future profits from new business (at point of sale) after cost
of required capital 	494 	609 	(19)
New business annualised premium equivalent6 	2 733 	2 564 	7
Annualised profit margin4 	2.5% 	3.1%
VitalityLife
Present value of future profits from new business (at point of sale) 	562 	153
Cost of required capital 	(159) 	(119)
Present value of future profits from new business (at point of sale) after cost
of required capital 	403 	34 	1 085
New business annualised premium equivalent7 	2 519 	2 094 	20
Annualised profit margin4 	2.3% 	0.2%
The term "annual premium equivalent" (“APE”) was disclosed as "annualised premium income" (“API”) in previous reporting periods. The term was changed to avoid conflict
with the new business disclosures in the published financial statements, which reference a different definition for "new business annualised premium income".
1 Health new business annualised premium equivalent is the gross contribution to the medical schemes. The new business annualised premium equivalent shown above
excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in respect of new
business written during the period but only activated after 30 June 2026. The total Health and Vitality new business annualised premium income written over the period
was R11 035 million (June 2025: R10 119 million).
2 Included in the Life and Invest embedded value of new business is R50 million (June 2025: R49 million) in respect of investment management services provided on off
balance sheet investment business. Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the
impact of which has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is due after
the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded after receipt. Invest new
business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the reporting period, including policies
whose first premium is due after the valuation date.
Embedded value statement continued
for the year ended 30 June 2026
84
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Table 7: Value of new business continued
The new business annualised premium equivalent of R3 704 million (single premium APE: R1 860 million (June 2025: R1 717 million)) shown above excludes automatic
premium increases, servicing increases in respect of existing business and Umbrella Funds and Other CEB new business annualised premium income. The total new business
annualised premium equivalent written over the period was R7 109 million (single premium APE: R1 979 million (June 2025: R1 806million)) and is set out in the table below:
R millions 	30 June 2026 	30 June 2025
New business annualised premium equivalent 	3 704 	3 270
Automatic premium increases 	2 269 	2 219
Servicing increases 	839 	761
Umbrella Funds and other CEB new business annualised premium income 	297 	383
New business annualised premium income 	7 109 	6 633
The new business annual premium equivalent of R3 704 million is split between Life of R803 million (June 2025: R735 million) and Invest of R2 901 million (June 2025:
R2 535 million).
Single premium Invest business is included at 10% of the value of the single premium. Section 14 transfers for Umbrella Funds are included at 10% of the fund value.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans, are shown in Table 5 as experience variances
and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date multiplied by the
Margin multiplied by the Annuity Factor plus the new business cash flows from point of sale to the valuation date. The assumptions for the Margin and Annuity Factor
are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised premium equivalent
shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as well as premiums in respect
of new business written during the period but only activated after 30 June 2026.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first premium is due
after the valuation date. The new business annual premium equivalent shown above excludes automatic contribution increases and servicing increases in respect of
existing business.
Embedded value statement continued
for the year ended 30 June 2026
85	84

-- 44 of 49 --

Basis of preparation
Table 8: Embedded value economic assumptions
R millions 	30 June 2026 	30 June 2025
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.50 	3.50
Risk discount rate (%)
– Health and Vitality1 	11.625 	13.875
– Life and Invest1 	11.625 	14.625
– VitalityHealth 	7.102 	6.573
– VitalityLife 	7.077 	6.734
Rand / GB Pound Exchange Rate
– Closing 	21.73 	24.34
– Average 	22.68 	23.48
Margin over Expense inflation to derive Medical Inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– Health and Vitality 	4.88 	5.66
– Life and Invest 	5.16 	6.41
United Kingdom 	3.77 	3.72
Pre-tax investment return (%)
South Africa 	– Cash 1 	7.50 	10.50
– Life and Invest bonds3 	9.00 	12.00
– Health and Vitality bonds3 	9.00 	11.25
– Equity 	12.50 	15.50
United Kingdom 	– VitalityHealth risk-free rate 	4.48 	3.95
– VitalityLife risk-free rate 	4.45 	4.11
– VitalityLife Investment return 	5.65 	5.26
Long-term corporation tax rate (%)
South Africa 	27 	27
United Kingdom 	25 	25
VitalityHealth margin assumption
– Margin (net of tax and cost of capital) (%) 	10.58 	10.56
– Annuity Factor 	7.57 	7.81
Projection term
– Health and Vitality 	20 years 	20 years
– Discovery Life - VIF 	40 years 	40 years
– Group Life 	20 years 	20 years
– VitalityLife 	No cap 	No cap
– VitalityHealth 4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted average inflation
is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.
Embedded value statement continued
for the year ended 30 June 2026
86
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM)
approach with specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set
such that the risk discount rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital
structure of the Group and the observed beta calculated using daily returns over a long time period. The observed beta is
calculated with reference to the ALSI. The assumed beta will only change if the capital structure of the Group and/or the
observed beta calculated using daily returns over a long time period suggest the beta assumption should depart significantly
from the assumption at the financial year-end. As beta values reflect the historic performance of share prices relative to the
market, they may not allow fully for non-market related and non-financial risk. Investors may want to form their own view on
an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where
available, augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience and augmented by future expectations.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and
Discovery Group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding
expenses of an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to an internally derived
nominal yield curve, which is consistent with the IFRS 17 reporting basis.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in
determining the net investment return assumption.
The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory
Authority yield curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption
following the implementation of IFRS 17. For consistency, VitalityLife has also transitioned to the use of a market inflation curve
from a long-term market view of inflation.
VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the Margin
multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future
lapse rates and premium increases. The Margin assumption reflects assumed profit margins after tax and the cost of required
capital. The assumptions underlying the Annuity Factor and Margin are set at the total book level, taking into account the
current experience and future expectations across all durations of in-force business. The economic components underlying the
Annuity Factor are reviewed at each reporting date; the non-economic components underlying the Annuity Factor and Margin
assumptions are reviewed periodically.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on
tangible assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which
is set based on the return on a portfolio of government and corporate bonds assumed to back the required capital. The Life
and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after
having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note
(“APN”) 107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been
adjusted to take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.
Embedded value statement continued
for the year ended 30 June 2026
87	86

-- 45 of 49 --

Basis of preparation
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values
reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-
financial risk. Investors may want to form their own view on an appropriate allowance for these risks which have not been
modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 30 June 2026 to changes
in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for
management action such as risk premium increases where future experience is worse than the base assumptions.
Table 9: Embedded value sensitivity Discovery
Group 	Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R millions
Adjusted net
worth
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Embedded
Value 	% change
Base 	30 397 	31 570 	(554) 	52 233 	(1 771) 	17 041 	(461) 	15 245 	(776) 	142 924
Impact of:
Risk discount rate + 1% 	30 397 	29 783 	(607) 	47 650 	(1 906) 	16 085 	(601) 	14 232 	(877) 	134 156 	(6)
Risk discount rate - 1% 	30 397 	33 552 	(493) 	57 678 	(1 605) 	18 107 	(303) 	16 403 	(624) 	153 112 	7
Lapses - 10% 	30 258 	32 595 	(580) 	57 107 	(1 822) 	19 185 	(519) 	16 213 	(867) 	151 570 	6
Interest rates - 1%1 	30 540 	31 533 	(532) 	53 325 	(1 818) 	18 107 	(490) 	14 750 	(886) 	144 529 	1
Equity and property market value - 10% 	29 923 	31 570 	(554) 	51 144 	(1 765) 	17 041 	(461) 	15 245 	(776) 	141 367 	(1)
Equity and property return + 1% 	30 397 	31 570 	(554) 	52 716 	(1 770) 	17 041 	(461) 	15 245 	(776) 	143 408 	—
Renewal expenses - 10% 	30 493 	34 715 	(513) 	53 087 	(1 754) 	18 697 	(461) 	15 623 	(754) 	149 133 	4
Mortality and Morbidity - 5% 	30 639 	31 570 	(554) 	55 424 	(1 655) 	20 471 	(461) 	15 710 	(754) 	150 390 	5
Projection term + 1 year 	30 397 	31 972 	(559) 	52 377 	(1 774) 	17 235 	(466) 	15 245 	(776) 	143 651 	1
1 All economic assumptions were reduced by 1%.
The following table shows the effect of using different assumptions on the embedded value of new business.
Table 10: Value of new business sensitivity Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R millions
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Value of
inforce
Cost of
required
capital
Value of new
business 	% change
Base 	1 506 	(51) 	555 	(86) 	554 	(60) 	562 	(159) 	2 821
Impact of:
Risk discount rate + 1% 	1 389 	(56) 	348 	(93) 	418 	(76) 	341 	(175) 	2 096 	(26)
Risk discount rate - 1% 	1 636 	(45) 	795 	(78) 	704 	(41) 	813 	(130) 	3 654 	30
Lapses - 10% 	1 603 	(55) 	776 	(89) 	933 	(70) 	792 	(183) 	3 707 	31
Interest rates - 1%1 	1 516 	(49) 	643 	(88) 	704 	(64) 	638 	(183) 	3 117 	10
Equity and property return + 1% 	1 506 	(51) 	587 	(86) 	554 	(60) 	562 	(159) 	2 853 	1
Renewal expenses - 10% 	1 710 	(48) 	609 	(85) 	739 	(60) 	635 	(155) 	3 345 	19
Mortality and Morbidity - 5% 	1 506 	(51) 	651 	(80) 	937 	(60) 	625 	(158) 	3 370 	19
Projection term + 1 year 	1 532 	(52) 	561 	(86) 	578 	(60) 	562 	(159) 	2 876 	2
Acquisition Expenses - 10% 	1 546 	(51) 	763 	(86) 	593 	(60) 	819 	(159) 	3 365 	19
1 All economic assumptions were reduced by 1%.
Embedded value statement continued
for the year ended 30 June 2026
88
89
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
88

-- 46 of 49 --

90
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
Annexure A
91 New business annualised
premium income
92 Income from non-insurance
business lines
92 Cash conversion ratio
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative performance
measures in addition to those measurements determined using IFRS Accounting Standards. These measures enhance the
comparability and understanding of the financial performance of the Group.
New business annualised premium income
for the year ended 30 June 2026
The new business annualised premium income (API) set out below provides a view of the scale of new business across all
operations of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group.
For instance, Discovery Health includes new business attributable to medical schemes for which it earns a fee in respect of
administration and marketing services.
New business API, increased by 6% for the year ended 30 June 2026 when compared to the corresponding prior period.
Group
2026
Group
2025
Change
%
Discovery Health1 	10 495 	9 573 	10%
Discovery Life 	3 244 	3 203 	1%
Individual Life 	2 811 	2 733 	3%
CEB 	433 	470 	(8%)
Discovery Invest 	3 865 	3 430 	13%
Discovery Insure 	1 390 	1 361 	2%
Discovery Vitality 	540 	546 	(1%)
New business API from Discovery SA 	19 534 	18 113 	8%
VitalityHealth 	2 871 	2 851 	1%
VitalityLife 	3 027 	2 499 	21%
Ping An Health Insurance (PAHI) own licence 	2 723 	3 023 	(10%)
New business API from Vitality 	8 621 	8 373 	3%
New business API of Group 	28 155 	26 486 	6%
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and offerings such
as Gap cover and FlexiCare cover. Closed Schemes refer to those restricted to certain employers and industries.
Calculation of new business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of
new single premium policies. It also includes both automatic premium increases and servicing increases on existing long-term
insurance policies. The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a
result of:
■ The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is
included from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the
table above, new business is included when the policy has been contractually committed.
■ Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table
above but excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new
business disclosures between the embedded value and the table above.
Annexure A
91	90

-- 47 of 49 --

Income from non-insurance business lines
for the year ended 30 June 2026
The table below includes income from business lines and activities not covered by the new business API definition, as outlined
in the previous table. For Discovery Bank, banking fees and commissions are presented net of related expenses. This
information differs from that provided in note A.4, which reflects the gross revenue streams for goods or services within the
scope of IFRS 15 Revenue from Contracts with Customers.
Group
2026
Group
2025 	Change %
Discovery Health – Income excluded from API measure 	1 740 	1 343 	30%
Discovery Bank 	3 070 	2 338 	31%
Discovery Bank – Net banking fee and commission income (NIR) 	1 815 	1 373 	32%
Discovery Bank – Net bank interest and similar income (NII)1 	1 255 	965 	30%
Vitality Global Markets income2 	2 472 	2 962 	(17%)
Total income from non-insurance business lines 	7 282 	6 643 	10%
1 Refer to A.1 Segment Information.
2 Vitality Global Markets income includes gross recurring and lump sum revenues earned by Vitality Group and solutions revenue from external clients, while that from
internal clients and rewards is specifically excluded.
Cash conversion ratio
for the year ended 30 June 2026
Cash conversion is calculated as Operating Cash Flow (per the Group shareholder free cash movement included in the
additional analyst information on Discovery’s website), divided by Normalised profit from operations (IFRS total, excluding the
IFRS Reporting Adjustments for shareholder investment income and fair value gains/(losses), as well as the once-off gain on
termination of the lease through the acquisition of 1 Discovery Place) net of Income tax expense (IFRS total) per A.1 Segment
Information. The Operating Cash Flow includes the net impact of funding sourced from financial reinsurance (whether
securitised from new business or the in-force book), which offsets new business acquisition costs, and the in-period
repayments in respect of previous funding taken.
Group
2026
Group
20251 	Change
Cash conversion ratio 	85% 	80% 	5pp
1 The prior year cash conversion ratio of 77% has been restated, as communicated in the interim results for the six months ended 31 December 2025, to allow for the
reversal of the IFRS Reporting Adjustments for shareholder investment income and fair value gains/(losses) to better align Normalised profit from operations and
Operating Cash Flow.
Annexure A continued
92
DISCOVERY AUDITED ANNUAL FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2026
1
Transfer secretaries
Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors
Nedbank Corporate and Investment Banking,
a division of Nedbank Limited
Secretary and registered office
AC Ceba (FCG) (F.Inst D)
Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE bond company code: 	DSYI
1 Discovery Place, Sandton, 2196
PO Box 786722, Sandton, 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors
ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), LM Chiume, VN Fakude1
R Farber, WM Hlahla, FN Khanyile, D Macready, KC Ramon, M Schreuder, B Swartzberg*,
BA van Kralingen, DM Viljoen* (Group Chief Financial Officer).
* Executive.
1 Appointed effective 1 September 2025.
Debt officer
DM Viljoen
Annual financial results
– prepared by L Motsepe-Setiloane CA(SA), K Modiba CA(SA), G Pieterse CA(SA),
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA1
Administration
93	92

-- 48 of 49 --



-- 49 of 49 --